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I Abstract 
Epilepsy is a chronic disorder of the brain and affects approximately 50 million people 
worldwide. It is, thus, one of the most common neurological diseases (World Health 
Organization, 2006). The main approach of epilepsy treatment is systemic drug 
application. The central nervous system (CNS), however, is a particularly challenging 
target for drug delivery. Systemic drug therapy is limited by the blood-brain-barrier 
(BBB), restricting the distribution of pharmaceuticals into the CNS. One approach to by-
pass the BBB is intrathecal (IT) administration of anti-epileptic drugs with direct 
application of substances into the cerebrospinal fluid (CSF). This study aimed to 
investigate whether IT application of anticonvulsant substances is a reasonable 
approach to treat epilepsy. The in-depth evaluation of IT drug application was 
performed in the genetic absence epilepsy rats from Strasbourg (GAERS). Seizures in 
GAERS rats closely resemble human absence seizures and can be detected as 
characteristic spike-and-wave discharges (SWDs) in the electroencephalogram (EEG). 
To quantify seizure occurrence in GAERS and assess the efficacy of anti-epileptic therapy, 
automated seizure detection based on EEG recordings was implemented. With this 
method, seizure detection was performed with an F-score of 96 %. 
The analysis of 12h and 24h recordings in untreated animals revealed circadian 
undulations of SWD activity with a peak of seizures between 2am and 4am. This 
observation was in agreement with earlier studies that showed that SWD activity 
depends on the vigilance level in rats (Drinkenburg et al., 1991). 
By intracerebroventricular (i.c.v.) injections, drug application into the CSF was archived. 
To this end, a guide cannula was implanted into the right lateral ventricle. Initially, the 
standard anti-absence drugs, ethosuximide (ETX), and valproate (VPA) (Manning et al., 
2003), were tested with this IT application approach. The treatment caused a substantial 
and dose-dependent reduction in SWD for both drugs and revealed that localized 
therapy with ETX is significantly more effective than with VPA. Additionally, the i.c.v. 
administration of ETX was dramatically more efficient than systemic ETX application of 
the same dose. The subsequent analysis of substance distributions in the brain after 
intracranial application suggested that the therapeutic effect was not caused by the 
indirect entry of ETX into brain parenchyma via the bloodstream but rather mediated by 
the direct entry from the CSF.  
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Additional experiments to explore the therapeutic efficacy of the neuropeptides 
Neuropeptide Y (NPY) and Somatostatin (SST) as potential alternative to standard drugs, 
did not reveal a robust anti-absence effect. Consequently, these neuropeptides were not 
considered potent substances for localized drug therapy in absence epilepsy. 
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II Zusammenfassung 
Epilepsie ist mit etwa 50 Millionen betroffenen Menschen weltweit eine der häufigsten 
Funktionsstörungen des Gehirns (World Health Organization, 2006). Die neurologische 
Erkrankung ist gekennzeichnet durch wiederkehrende epileptische Anfälle, die häufig 
durch eine systemische medikamentöse Therapie behandelt werden können. Eine große 
Herausforderung der systemischen Therapie ist allerdings der Transport von 
Wirkstoffen in ihr Zielgebiet, da das zentrale Nervensystem (ZNS) durch die Blut-Hirn-
Schranke geschützt wird. Durch die hohen Serumkonzentrationen, die notwendig sind, 
damit eine therapeutische Konzentration im Gehirn erreicht werden kann, kann es zu 
peripheren Nebenwirkungen kommen. Eine Möglichkeit die Blut-Hirn-Schranke zu 
umgehen, ist die direkte Injektion von antiepileptischen Wirkstoffen in den Liquorraum, 
die sogenannte intrathekale Applikation (IT-Applikation).  
In der vorliegenden Arbeit wurde untersucht, ob die IT-Applikation von 
antiepileptischen Wirkstoffen eine mögliche Alternative zur systemischen 
Epilepsietherapie darstellen kann. 
Hierzu wurde die lokale Applikation verschiedener Wirkstoffe in einem 
Modellorganismus für Abcense-Epilepsie, den genetic absence epilepsy rats from 
Strasbourg (GAERS), getestet. Die Tiere zeigen Anfälle, die sich durch Spike-Wave-
Aktivität (SWD) im EEG manifestieren. Anhand der Anfallshäufigkeit der Tiere kann die 
Wirksamkeit einer Therapie bewertet werden. Zu diesem Zweck wurde eine 
automatische computerunterstützte Detektion von Anfällen implementiert.  
Mittels einer Kanüle im rechten lateralen Ventrikel (intracerebroventrikulär – i.c.v.) der 
Tiere konnten Wirkstoffe direkt in den Liquor appliziert werden. Untersucht wurden 
unter anderem die Wirkstoffe erster Wahl für Absence-Epilepsie, Valproat (VPA) und 
Ethosuximid (ETX). Für beide Medikamente konnte eine starke 
konzentrationsabhängige antiepilepitische Wirkung nach i.c.v. Therapie nachgewiesen 
werden. Das Medikament ETX zeigte eine stärkere sowie länger anhaltende Wirkung im 
Vergleich zu VPA. Darüber hinaus war die lokale Therapie mit einer geringen Dosis von 
ETX signifikant effektiver in der Behandlung epileptischer Anfälle als die systemische 
Therapie mit der gleichen Medikamentendosis.  
Durch Untersuchungen zur Substanzverteilungen im ZNS, konnte die Annahme bestätigt 
werden, dass die therapeutische Wirkung nicht durch den indirekten Eintritt von ETX in 
das Gehirnparenchym über den Blutkreislauf verursacht wird, sondern durch den 
direkten Eintritt ins Gehirn aus dem Liquor.  
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Des Weiteren wurden die Neuropeptide Neuropeptid Y (NPY) und Somatostatin (SST) 
auf ihre antiepileptische Wirkung nach i.c.v. Gabe getestet. Neuropeptide sind attraktive, 
potenzielle Alternativen zu den klassischen Antiepileptika, da sie als endogene 
Neuromodulatoren schon in sehr geringen Konzentrationen wirksam sind. Die lokale 
Applikation der Neuropeptide NPY und SST zeigte jedoch bei GAERS-Ratten keine 
antiepileptische Wirkung. Daher wurden die getesteten Neuropeptide für eine 
lokalisierte medikamentöse Therapie von Abcense-Epilepsie nicht weiter in Betracht 
gezogen. 
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1 Introduction 
1.1 Epilepsy – a disorder of the central nervous system 
Epilepsy is a chronic disorder of the brain and affects approximately 50 million people 
worldwide. It thus is one of the most common neurological diseases (World Health 
Organization, 2006). Spontaneous, transient, and periodic recurring seizures caused by 
aberrant changes in the neural activity, are a hallmark feature of epilepsy.  
The causes of epilepsy are manifold, and the International League Against Epilepsy 
(ILAE) classified 2017 the etiologies into six main categories: structural, genetic, 
infectious, metabolic, immune, or unknown.  
Moreover, epilepsies show a variety of clinical manifestations with many distinct seizure 
types. On that basis, the ILAE proposed a standardized classification of epileptic seizures 
(fig. 1.1). The classification of seizures can be essential to understand the causes 
underlying epileptic attacks and to develop treatment strategies (Scheffer et al., 2017). 
Seizures can be focal or generalized, determined by the origin of seizure onset. Though 
the origin of onset remains unknown in some cases.  
  
Figure 1.1: Types of epileptic seizures 
The panel is adapted from the basic ILAE 2017 classification of seizure 
types (Scheffer et al., 2017). Seizures can be grouped into three main 
seizure types depending on their onset: focal, generalized, and 
unknown. 
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In generalized seizures the abnormal electrical activity instantly spreads over both 
hemispheres of the brain, whereas focal seizures originate in small groups of neurons 
and are restricted to one hemisphere. The symptoms in focal seizures depend on the 
affected brain areas and the seizures are not necessarily accompanied by an alteration 
of consciousness. In contrast to that a complete loss of awareness is a typical feature in 
generalized seizures. The main subtypes of generalized seizures are absence (petit mal) 
and tonic–clonic seizures (grand mal). Absence seizures do not show motor symptoms, 
but tonic-clonic seizures can be accompanied by spasms, shaking, stiffening, and the loss 
of muscle tone. Generalized seizures constitute nearly one-third of all epilepsies (for a 
review see Panayiotopoulos, 2005). 
1.2 Absence Epilepsy and the thalamocortical circuit 
Absence seizures are the prototype of generalized and non-convulsive seizures and are 
a typical feature of absence epilepsy. This type of epilepsy is one of the most common 
forms of childhood epilepsy, and approximately 7 per 100.000 children under the age of 
15 are affected yearly (Olsson, 1988). Absence epilepsy is suggested to have a 
multifactorial genetic etiology. The precise identification of the genetic causation 
underlying the disease is not resolved yet. However, gene mutations associated with the 
γ-aminobutyric acid type A (GABAA) receptor and mutations in the T‐type calcium 
channel gene CACNA1 have been found in patients with childhood absence epilepsy 
(Liang et al., 2006; Wallace et al., 2001). 
The seizures start between three and eight years of age, and around 70% of the affected 
children show spontaneous remission around adolescence. Patients with absence 
epilepsy can suffer from up to 200 seizures per day. The typical absence seizures are 
characterized by sudden seizure onset and termination, accompanied by brief 
impairment of consciousness and behavioral arrest. Furthermore, absence seizures are 
associated with characteristic synchronized ~3 Hz spike-and-wave discharge (SWD), 
which can be detected in the electroencephalogram (EEG) (Crunelli and Leresche, 2002; 
Lockman, 1989; Manning et al., 2003). 
 
A dysfunctional interplay between thalamic and cortical structures appears to promote 
the emergence and maintenance of absence seizures (Lüttjohann and van Luijtelaar, 
2015; Steriade, 1990). The thalamus is a subcortical structure, that is critical for relaying 
sensory information from the periphery to specific areas of the cerebral cortex. 
Additionally, extensive reciprocal thalamocortical connections are crucial for the 
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generation of sleep-related but possibly also paroxysmal oscillations in the cortex 
(Beenhakker and Huguenard, 2009; McCormick and Bal, 1997). The principal 
thalamocortical circuit is formed by three sets of neurons: inhibitory neurons in the 
reticular thalamic nucleus (NRT), excitatory thalamocortical neurons (TC) in the dorsal 
thalamic nucleus, and excitatory pyramidal cortical cells (fig. 1.2) (Sherman and Guillery, 
1996).  
 
The NRT is an essential source for intra-thalamic inhibition. Its neurons contain the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) (for review see Halassa and 
Acsády, 2016). NRT neurons send inhibitory projections to TC neurons but receive 
glutamatergic excitatory input from both the thalamus and cortex (Jones, 1975; Pinault 
et al., 1997). The NRT is interconnected by inhibitory GABAergic synapses but also via 
electrical coupling through gap junctions and thus can precisely modulate the scale of 
thalamic inhibition (Landisman et al., 2002). The NRT, which provides both feed-forward 
and feed-back inhibition to TC neurons, is consequently an essential modulator for the 
thalamocortical information flow (fig. 1.2B). 
 
TC neurons exhibit two distinct firing modes, known as tonic and burst firing  
(fig. 1.2C)(Ramcharan et al., 2000; Sherman, 2001). The switch between these firing 
modes depends on the activation state of low-threshold T-type Ca2+ channels (T-
channels) and is underlying various vigilance and sleep stages (Crunelli et al., 2014). T-
channels are prominently expressed in the thalamus and are encoded by genes from the 
Cav3 family (for review see Chen et al., 2014). Tonic firing occurs at the membrane 
resting potential during which T-channels are inactive. In this mode, TC neurons respond 
to external stimuli with unitary action potentials.  
 
In contrast, burst firing requires a hyperpolarization of TC cells below approximately  
-65 mV, which de-inactivates the T-channels. Hyperpolarization-activated channels (e.g. 
HCN-channels) promote cationic currents known as the h-currents (Ih), which can 
depolarize the cells again (McCormick and Bal, 1997). A sufficient depolarization will 
than activate Ca2+ inward currents (It), leading to a low threshold spike, which triggers 
the burst of several, fast action potentials at a certain threshold (McCormick and Bal, 
1997; Zhan et al., 2000). Thus, NRT mediated inhibition effectively activates TC neurons 
by promoting post-inhibitory rebound burst firing. As a consequence, the activity is 
transmitted back to NRT and the cortex, which causes a recurring excitatory cycle 
generating thalamocortical oscillations. 
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Several studies associate the presence of post-inhibitory rebound burst firing in TC 
neurons with the generation and/or maintenance of absence seizures  
(Huntsman, 1999; von Krosigk et al., 1993). This view is supported by the observation 
of increased SWD duration in a rat model of absence epilepsy, through microinjection of 
γ-vinyl-GABA, an irreversible inhibitor of GABA transaminase into the thalamic relay 
nucleus. In contrast, the local activation of GABA transmission in the NRT significantly 
suppressed seizure activity (Liu et al., 1991). Moreover, Sorokin et al. (2017) have used 
optogenetic methods, both in vitro and in vivo, to artificially switch between tonic and 
burst firing modes in TC neurons in an absence epilepsy model. Their findings indicate 
that synchronous burst firing of TC neurons is required for the emergence of absence 
seizures.  
 
However, other studies contradict this view by showing largely paused TC burst activity 
during SWDs (Pinault et al., 1998; Steriade and Contreras, 1995). Based on in vivo unit 
recordings in freely moving rats McCafferty et al. (2018) recently demonstrated, that 
ictal burst firing of TC neurons is reduced, and instead, tonic firing is elicited during 
absence seizures. Furthermore, they state that the blockage of T-channels in TC neurons 
had no effect on seizures activity, while the same blockage in cortex and NRT suppresses 
SWDs.  
 
The relative contribution and interactions of thalamocortical structures, underlying 
SWD generation, and maintenance remains controversially debated. However, over the 
last years, it has come to the fore, that absence seizures are initiated in the cortex, 
specifically in the primary somatosensory (S1) cortex (for review see Meeren et al., 
2005). This “cortical focus theory” was inspired by the finding of Meeren et al. (2002), 
that SWDs always started in the cortex, leading the thalamus. The study was based on 
electrophysiological recordings in a rat model of absence epilepsy.  
 
The hypothesis of an epileptic focus in the S1 cortex could be supported by 
pharmacological studies (cf. Chapter 1.4) (Meeren et al., 2002; Polack et al., 2009; 
Sitnikova and van Luijtelaar, 2004) and further analysis of the spatiotemporal properties 
of network oscillations during epileptic activity (Meeren et al., 2002; Polack et al., 2007).  
 
Moreover, human studies also revealed a critical role of the cortex in the generation of 
SWDs (Holmes et al., 2004). Although the cortex is still the most probable site of seizure 
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emergence, the thalamus is proposed to be crucial for maintenance and termination of 
SWDs (Lüttjohann and van Luijtelaar, 2015). 
 
  
Figure 1.2: Cortico-thalamo-cortical interactions underlying SWDs  
A) Schematic representation of a coronal brain section of a rat illustrating the 
brain areas relevant for the emergence and maintenance of SWDs. NRT, nucleus 
reticularis thalami; TC, thalamo-cortical neurons of the dorsal thalamus; Cortex, 
primary somatosensory cortex. Coordinates are adapted from the atlas of 
Paxinos and Watson (Paxinos and Watson, 2006) with bregma as a reference. 
B) Model of the cortico-thalamo-cortical network consisting of excitatory 
thalamocortical (TC) and inhibitory reticular thalamic nucleus (NRT) neurons 
in the thalamus and excitatory pyramidal cells in the cortex. Most probably, 
SWDs are generated in cortical areas. The thalamus is proposed to tip the 
system over towards a pro epileptic state and function as a resonator in SWD 
maintenance. C) Characteristic patterns of tonic and burst firing in TC neurons. 
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1.3 The Genetic Absence Epilepsy Rat from Strasbourg – an 
established model for absence epilepsy  
Several of the key findings regarding the pathomechanisms of absence epilepsy were 
obtained in genetic rodent models. One of the most commonly used and best established 
models in experimental studies on this type of epilepsy is the Genetic Absence Epilepsy 
Rat from Strasbourg (GAERS) (for review see Depaulis et al., 2016 and Marescaux et al., 
1992). The other well-established model in absence epilepsy research is the WAG/Rij 
rat, and both models show similar characteristics (for a review see Coenen and van 
Luijtelaar, 2003).  
The GAERS strain was first described in 1982 by (Vergnes et al., 1982). The group 
observed that around thirty percent of their Wistar rats colony developed spontaneous 
seizures, which closely resemble human absence seizures. In line with findings of genetic 
data from human patients, a functional mutation of the Cacna1h gene encoding the 
Cav3.2 T-type Ca2+-channel was identified in GAERS. This mutation results in faster 
recovery from T-channel inactivation and greater charge transference while high-
frequency bursts (Powell et al., 2009). 
 
During the seizures, the animals show subtle behavioral changes consisting mainly of 
behavioral arrest, which can be accompanied by rhythmic twitching of the vibrissae and 
jaw muscles. Besides that, the EEG of GAERS displays bilateral synchronous SWDs over 
the entire cortex, closely resembling the human SWDs characteristics. The seizure 
amplitudes vary between 300 – 1000 µV, and the seizure duration can last up to 60 
seconds. However, it is interesting to note that the mean frequency of the SWDs in GAERS 
is in the range of 7 – 11 Hz, whereas classical SWD complexes in humans show 
frequencies around 3 Hz. 
The occurrence of SWDs depends on the vigilance level of the rats. Accordingly, seizure 
activity predominantly occurs during passive wakefulness and somnolence, while SWDs 
are sporadic during active wakefulness, slow-wave, and paradoxical (rapid-eye-
movement, REM) sleep (Drinkenburg et al., 1991; Van Luijtelaar and Coenen, 1988). The 
modulating impact of vigilance on the SWD-frequency has also been observed in humans 
(Kellaway et al., 1980). The relative age of manifestation and the dynamics of 
progression of the disease however differ between GAERS and humans. Whereas in 
humans absence seizures start at an early age (3 – 8 years of age) and usually disappear 
with puberty, absence seizures in GEARS progressively mature over a period of several 
months postnatally. Only after about four months all rats show SWDs. After six months 
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the maximum number of seizures is reached and will then persist over the lifetime of the 
rat.  
A great advantage of the GAERS model is the nearly identical pharmaceutic profile with 
humans. The relatively easy monitoring and detection of epileptic brain activity 
combined with the predictive validity of GAERS makes it an excellent model to study 
novel therapeutic strategies in absence epilepsy.  
1.4 Ethosuximide and valproate in the treatment of absence 
epilepsy.  
Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment, whereas 25 – 30 % 
of the patients with epilepsy are pharmacoresistant (World Health Organization, 2006). 
Pharmacoresistance describes the condition, in which epileptic seizures cannot or can 
only be controlled partially by AEDs. A detailed definition of drug-resistant epilepsy was 
introduced in 2010 by the ILAE (Kwan et al., 2010). Non-pharmacological treatment 
options include resection surgeries, vagus-nerve stimulation, or a ketogenic diet. 
However, the non-pharmacological therapy is only feasible and successful in few 
selected cases (for a review see Kwan et al., 2011). 
Over the last decades ethosuximide (ETX) and valproate (VPA) have been the drugs of 
choice in childhood absence epilepsy. The drugs topiramate, levetiracetam, and 
lamotrigine also show anti-absence efficacy in humans and GAERS (for a review see 
Manning et al., 2003). However, because of a lower efficacy, safety, and tolerability 
compared to ETX and VPA, they are clinically less relevant (Glauser et al., 2010). 
Moreover, other substances such as carbamazepine, vigabatrin, and gabapentin, which 
are highly effective drugs in the treatment of other forms of epilepsy, have an 
aggravating effect on seizures activity in both humans suffering from absence epilepsy 
but also GAERS. Commonly, drugs that facilitate the action of the inhibitory transmitter 
GABA show very good therapeutic efficiency in the treatment of various forms of 
epilepsy, as they increase chloride influx or potassium outflux and thus tend to 
hyperpolarize neurons. However, these drugs appear to exacerbate SWD appearance, 
which supports the view that absence epilepsy is perhaps related to a predominance of 
inhibitory activity (cf. Chapter 1.2). 
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Ethosuximide  
Ethosuximide (2-ethyl-2-methylsuccinimide; ETX) was introduced in the 1950s and has 
since been considered first-line therapy in absence epilepsy (Zimmerman and 
Burgemeister, 1958). ETX is one out of three succinimides (ethosuximide, methsuximide 
and phensuximide) showing anticonvulsant activity, whereas ETX produces the greatest 
efficacy against absence seizures and is relatively well-tolerated (Browne, 1983). 
However, dose-dependent side effects related to the gastrointestinal tract, central 
nervous system, and hematopoiesis have been described (for a review see Gören and 
Onat, 2007). The apparent volume of distribution of ETX is about 0.7 L/kg in humans 
(Buchanan et al., 1969) and was found to be very similar in rodents (Bachmann et al., 
1988). The volume of distribution is an estimate about how much of a drug distributes 
from the blood plasma into other body compartments. The larger the volume of 
distribution is, the more likely that the drug can distributes into the body tissues 
including the brain. Indeed, Patel et al. (1977) could show for ETX that it distributes 
homogenously throughout different brain areas in rats. Hepatic metabolism is the 
primary elimination route of ETX, and several metabolites with no significant activity 
have been reported (Millership et al., 1993). The elimination half-life of ETX in rodents 
ranges between 10 and 16 hours (Teschendorf and Kretzschmar, 1985) and in adult 
humans from 30 to 60 hours (Buchanan et al., 1969).  
 
ETX has a narrow therapeutic profile, and the effect of the AED is selective for absence 
seizures. Until today the anti-absence mechanisms of ETX are not fully understood. In 
the classical view, ETX blocks It currents in TC neurons and therefore suppresses burst 
firing in these cells (Davies, 1995; White, 1999). This hypothesis is based on studies in 
brain slices of rats and guinea pigs, which showed a decrease of low-threshold calcium 
currents in thalamocortical neurons induced by therapeutically relevant ETX 
concentrations (0.2 – 0.75 mM) (Coulter et al., 1989; Macdonald, 1989). Later this could 
also be shown for NRT neurons (Huguenard and Prince, 1994). This explanation of the 
mode of action of ETX appeared to be sufficient, as the assumption that burst firing in TC 
neurons is crucial for the generation of pathological SWDs is widely accepted (cf. Chapter 
1.2). However, other studies using the same recording method failed to detect the action 
of ETX on It currents. Instead, Leresche et al. (1998) claimed that suppressed burst 
activity rather results from a reduction of persistent Na+ currents, and Ca2+- activated K+ 
currents in thalamic and cortical neurons.  
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In vivo studies revealed immediate and robust anti-absence action produced by ETX 
injection into the S1 cortex of GAERS. ETX injections in other cortical areas appeared to 
be less effective (Gülhan Aker et al., 2010; Manning et al., 2004). Indeed, microinfusions 
of ETX into the NRT and ventrobasal (VB) thalamus only partially decreased SWD after 
a time delay of approximately 30 minutes (Richards et al., 2003). The ventrobasal 
structure is strongly connected to the cortex via TC neurons (Sherman and Guillery, 
1996). The outcome of these studies furthermore questions the thalamus as the 
exclusive site of action of ETX, though it supported the “cortical focus theory”. A more 
recent study showed that ETX elevates synaptic inhibition in cortical areas by increasing 
spontaneous GABA release with no change in glutamate release. The authors thus 
concluded that cortical inhibition could contribute to the anti-absence effect of ETX 
(Greenhill et al., 2012). 
 
A recent review by Brigo et al. (2019) aimed to determine the best choice of antiepileptic 
drugs in absence epilepsy by comparing clinical studies on the efficiency of valproate, 
ethosuximide, and lamotrigine. According to that, ETX represents the optimal initial 
monotherapy for patients suffering from absence seizures. 
Valproate  
Valproate (VPA) is a simple branched short-chain fatty acid, that was first synthesized 
by Burton in 1882. The drug's antiepileptic properties were discovered eighty years later 
(for a review see Löscher, 1999). VPA is also used in other neurological conditions such 
as migraine, neuropathic pain, or traumatic brain injuries (for a review see Romoli et al., 
2019). The volume of distribution for VPA in rats is 0.66 L/kg (Löscher, 1999b), and the 
drug shows a rapid penetration into the brain (Lindberger et al., 2008). The elimination 
half-life of VPA in adult humans ranges from 9 to 18 hours (Löscher, 1978). Because of 
the relatively short elimination half-life of approximately two hours in rodents (Löscher, 
1978), the anticonvulsant effects can be detected only for minutes or tens of minutes 
after application. Consequently, high doses of valproate are needed to evoke a more 
sustained suppression of seizures in animal models (Löscher, 2002). There are several 
routes of VPA metabolism in humans, and some metabolites of VPA exert anticonvulsant 
activity. However, the brain concentrations of these metabolites are too low to 
contribute to the drug's anticonvulsant effect significantly (Löscher, 1999b). 
Although VPA is claimed to be a generally well-tolerated AED, several dose-related side 
effects have been described, such as weight gain, gastrointestinal, neurological, and 
metabolic disorders (for a review see Johannessen and Johannessen, 2003).  
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VPA is one of the drugs of choice for generalized absence seizures, but in contrast to ETX, 
VPA is highly effective in several seizures types such as absences, myoclonic, and 
generalized tonic-clonic seizures (Davis et al., 1994). As for ETX, the anti-absence 
mechanisms of action for VPA are not fully understood. However, a broad spectrum of 
antiepileptic properties has been proposed for VPA. Several studies demonstrated that 
VPA is enhancing the inhibitory activity of GABA by increasing its availability and 
facilitating GABA mediated responses (Chapman et al., 1982; Cunningham, 2003; 
Löscher, 1999b). Interestingly other drugs that potentiate the action of GABA appear to 
exacerbate the appearance of SWDs. However, enhanced GABAergic inhibition after 
valproate administration was found to be specific to particular brain areas such as the 
cerebral cortex (Frank Baldino and Geller, 1981), which would be in line with the 
therapeutic mechanisms proposed for ETX by Greenhill et al. (2012) (cf. Chapter 1.2). 
A further antiepileptic mechanism of action of valproate appears to be an effect on ion 
channels. VPA has been shown to block Na+-currents and repetitive firing in cortical 
neurons (McLean and Macdonald, 1986; Taverna et al., 1998). Moreover, Broicher et al., 
2007 found that both VPA and ETX block IT currents in isolated thalamic neurons. 
However, they reported that the effect of ETX is considerably more robust compared to 
VPA. Finally, if administered in high concentrations, VPA seems to increase the 
amplitude of the late potassium outward currents, which increases the threshold for 
epileptiform activity (Walden et al., 1993).   
  
Serralta et al. (2006) revealed that acute intracerebroventricular (i.c.v.) injections of VPA 
(4.5mg/kg) suppressed seizures in a kindling epilepsy model. Though the treatment was 
accompanied by severe ataxia and, sedation. Furthermore, the duration of the effect did 
not exceed 15 minutes. Indeed, the study further showed that by continues i.c.v. infusion 
of VPA seizures could be controlled without producing obvious side effects.   
In a neocortical rat epilepsy model, epileptiform activity was reduced through a cortical 
applied valproate releasing implant (Rassner et al., 2015). However, intracranial VPA 
application in absence epilepsy has to our knowledge not been described yet.   
 
Finally, it has been shown that the combined treatment with ETX and VPA appeared to 
be infra-additive compared to the individual compounds in WAG/Rij rats (van Rijn et al., 
2004), which could indicate that the two AEDs share some common cellular or molecular 
targets. 
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1.5 Neuropeptides in the treatment of absence epilepsy  
Pathophysiological brain activity is initiated by an imbalance of excitatory and inhibitory 
activity in the brain. Neuropeptides are potent modulators of neuronal activity. They 
work through G-Protein-coupled receptors to modulate synaptic activity by adjusting 
neurotransmitter release or affecting ion channels, e.g., increasing potassium 
permeability or neurotransmitter receptors (Baraban and Tallent, 2004). Accordingly, 
neuropeptides are investigated as alternative anticonvulsant substances for the classical 
AEDs (for review see Kovac and Walker, 2013). Already one neuropeptide, the 
adrenocorticotropic hormone, is currently being used as a therapy for epilepsy 
(Mytinger and Joshi, 2012).  
The term neuropeptide comprises a number of different endogenous peptidergic 
neuromodulators such as neuropeptide Y, somatostatin, galanin, angiotensin, and 
neurotensin, which are stored in large dense vesicles mainly in interneurons. Their 
release is calcium-dependent and is triggered by the repetitive firing of action potentials 
at high frequencies, which can also be associated with epileptiform discharges. 
In several model organisms neuropeptides show anti-epileptic efficacy at extremely low 
doses. As endogenous substances, the neuromodulators are hardly affected by active 
elimination mechanisms in the CNS (Kovac and Walker, 2013). Thus, neuropeptides 
could be potential alternatives for AEDs considering the development of intracranial 
drug delivery applications. 
Neuropeptide Y 
One of the best-investigated neuropeptides in the context of epilepsy is the neuropeptide 
Y (NPY). NPY is a short peptide that is widely distributed in the CNS but can also be found 
in the peripheral nervous system and other tissues. NPY appears to have a modulating 
role in numerous physiological processes, including cortical excitability, circadian 
rhythms, stress responses, and food intake. Five G-protein coupled receptors (Y1, Y2, Y4, 
Y5, and Y6) have been identified for NPY (for a review see Benarroch, 2009). The 
mechanisms underlying the NPY-mediated reduction of epileptiform discharges are not 
entirely understood and the involvement of the different NPY receptor subtypes is 
controversially debated. Though, patch-clamp recordings in rat brain slices revealed that 
exogenously applied NPY affects inhibitory as well as excitatory synaptic events in the 
cortex, most probably through acting on multiple receptors (Bacci et al., 2002). 
Moreover, NPY potentially inhibits excitatory synaptic transmission in the hippocampus 
of rodents by activating either Y2 or Y5 receptors. Both receptors have been associated 
with decreased glutamate release in this brain area (El Bahh et al., 2005; Ho et al., 2000). 
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These effects overall decrease the excitability in neuronal networks, which is suggested 
to be underlying the antiepileptic effect of NPY, described for several animal models of 
epilepsy (for a review see Clynen et al., 2014). 
 
The anticonvulsant actions of NPY have been mainly studied in acquired limbic 
epilepsies (e.g., temporal lobe epilepsy) but were also demonstrated in generalized 
epilepsies (Kofler et al., 1997; Noè et al., 2008; Sørensen et al., 2009). Two studies 
reported an anti-absence effect of NPY in GAERS when administered directly into the 
brain or cerebrospinal fluid  (van Raay et al., 2012; Stroud et al., 2005). 
Stroud et al. (2005), described a significant reduction of SWDs after i.c.v. injection of very 
low doses of the neuropeptide (6 nmol) in GAERS; though, seizure suppression was only 
assessed for 90 min after treatment. Interestingly, an equal effect could be achieved by 
the i.c.v. application of a Y2-selective agonists, whereas the selective activation of other 
receptor subtypes produced significantly weaker seizure suppression (Morris et al., 
2007). Therefore, the authors argued that the anti-absence action of NPY is 
predominantly exerted via Y2 receptor subtypes. 
The focal administration of NPY into the secondary somatosensory (S2) cortex showed 
an anti-absence action in a dose-dependent manner. Interestingly the microinjection of 
NPY into the S1 cortex appeared to be less effective (van Raay et al., 2012). These 
findings could indicate differences in mechanisms of action compared to ETX because 
ETX shows the best anticonvulsant efficacy when applied to S1 cortex (Manning et al., 
2004). 
Somatostatin 
Somatostatin (SST) is a small neuropeptide involved in the regulation of the endocrine 
system, affecting neurotransmission and cell proliferation. Besides the hypothalamus, 
SST can be found in various other brain areas, including the amygdala, hippocampus, 
striatum, cerebral cortex, olfactory regions, and the brainstem (Viollet et al., 2008). The 
neuropeptide acts on G-protein–coupled receptors SST1, SST2, SST3, SST4, and SST5 (Patel 
et al., 1977).  
 
In 1987, Sloviter showed in a rat model for temporal lobe epilepsy, the selective loss of 
SST containing neurons in the hilus of the dentate gyrus. These results indicated for the 
first time that SST could be involved in the pathology of epilepsy. Subsequent studies 
claimed robust antiepileptic properties of SST with the major site of action being in the 
hippocampus (for review see Tallent and Qiu, 2008). The antiepileptic effect could be 
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explained by inhibited presynaptic glutamate release via the activation of SST2 receptors 
(Kozhemyakin et al., 2013). 
Moreover, it has been demonstrated that i.c.v. treatment with SST is an effective method 
to decrease kindled seizures in rodents (Mazarati and Telegdy, 1992). Somatostatin and 
NPY showed similar antiepileptic activity in a model of self-sustaining status epilepticus. 
Both neuropeptides induced strong, but transient suppression of spikes and seizures 
(Mazarati and Wasterlain, 2002). The effect of SST on generalized absence seizures has 
to our knowledge not been described yet. Nevertheless, SST could be a potent 
anticonvulsant substance for novel therapeutics approaches. 
1.6 Drug delivery for the treatment of neurological diseases 
Only in 70 % of people diagnosed with epilepsy, the use of AED can sufficiently suppress 
seizure activity (World Health Organization, 2006). In other words, about 30 % of 
sufferers cannot be adequately treated by oral anti-epileptic therapy. One reason for the 
high ratio of pharmacoresistance could be the low availability of AEDs in the central 
nervous system (CNS) after systemic treatment (for a review see Sharma et al., 2015). 
One great obstacle in systemic anti-epileptic pharmacotherapy is the blood-brain-
barrier (BBB), limiting the uptake of active agents in the brain. The BBB is enclosing non-
fenestrated blood vessels in the CNS and is mainly composed of endothelial cells 
connected by tight junctions, astrocytic endfeet, and pericytes (for review see Oby and 
Janigro, 2006). The BBB forms, on the one hand, a strong diffusion barrier between 
periphery and brain tissue and, on the other hand, also very efficiently removes drugs 
from the CNS by efflux transporters present in the BBB (Löscher and Potschka, 2005). 
The restricted BBB passage of active agents is underlying the need for excess peripheral 
drug concentrations, limiting their applicability through emerging peripheral side 
effects such as gastrointestinal, hepatic and pancreatic affection, teratogenicity, blood 
count abnormalities, and others. Moreover, systemic treatment of epilepsy and other 
brain diseases with potentially effective drugs is unfeasible due to BBB-impermeability 
of large or polar molecules (Pardridge, 2005). 
 
One approach to by-pass the BBB is intrathecal (IT) administration of substances. IT 
administration describes the application of substances directly into cerebrospinal fluid 
(CSF) that is contained in the thecal sac of the brain (for review see Fowler et al., 2020). 
Transporting neuroactive components into the CNS via the CSF potentially holds several 
advantages over systemic treatment: IT delivery would widen the spectrum of potential 
Introduction  Chapter 1 
 26 
drugs by those that do not readily cross the BBB. Furthermore, this application method 
could lead to increased concentrations of conventional active substances in the brain 
while minimizing side effects caused by off-target drug exposure in other body 
compartments. Besides, drugs delivered into the CSF may be less affected by 
metabolization prolonging their half-life (Misra et al., 2003). 
 
However, the application of agents into the CSF has also been critically discussed. It has 
for example been suggested that the drugs could be affected by rapid clearance because 
of the high turnover rate of the CSF. Though, the CSF turnover rate drastically varies 
between species. In humans the CSF volume is replaced 3 – 5 times a day, (Pardridge, 
2016); whereas in rats the turnover rate is between 9 – 12 times a day (Chiu et al., 
2012a). Furthermore, it has been argued that many molecules show very poor 
penetration into the parenchymal brain tissue after application into the CSF (Blasberg et 
al., 1975; Yan et al., 1994). Along these lines Pardridge (2016) argued that IT application 
rather works as a slow intravenous infusion by drug clearance into the bloodstream and 
subsequent distribution in the brain. 
Drug transportation via the cerebrospinal fluid 
In order to assess the potential of the IT administration routs, it is advantageous to 
understand the dynamics of the CSF flow. Though CSF flow is highly complex, and several 
aspects of the flow dynamics are not entirely understood (for review see Linninger et al., 
2016). 
In healthy humans the total CSF volume ranges from 250 ml to 400 ml and in rats 
between 200 µl – 400 µl (Chazen et al., 2017; Chiu et al., 2012b). The most considerable 
volume of the CSF resides intracranially in the ventricular system, cisterns, and 
subarachnoid space (SAS) (fig. 1.3). The ventricular system of rodents is turned by 90° 
compared to the human ventricular system apart from that the ventricular anatomy is 
very similar. The CSF flow throughout the CNS are maintained by unidirectional low 
active circulation (Di Chiro, 1966) and fast pulsatile movements, which are bidirectional 
and synchronized with the cardiac cycle (Reubelt et al., 2009). The steady circulation is 
driven by balanced CSF secretion and reabsorption, which is also essential for 
maintaining intracranial pressure. The CSF flows from the lateral ventricles (LVs) 
through the intraventricular foramen directly into the third ventricle. Passing the third 
and fourth ventricles, the CSF enters the cisterns surrounding the cerebellum and exits 
into the cranial and spinal SAS (fig. 1.3). The CSF movement is additionally supported by 
beating cilia of the ventricle’s ependymal cells.  
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In the classic view, a significant portion of the CSF is secreted by the choroid plexus (CP) 
in the ventricles. However, according to a new hypothesis, the CSF is permanently 
produced and absorbed in the whole CSF system, as capillary walls in the surrounding 
CNS reabsorb and filtrate the fluid (for a review see Orešković and Klarica, 2010). 
Still the CP epithelial cells, which are connected via tight junctions and enclosing blood 
vessels, are an essential component of the blood-CSF-barrier. In contrast to the BBB, the 
capillaries of the CP are fenestrated. Therefore, the exchange of fluids and molecules 
between CSF and blood is facilitated (for review see Spector et al., 2015). In humans, the 
arachnoid granulation functions as the CSF reabsorption route.  
The CSF flow through the extracellular brain space is another possible route that is 
essential for substrate delivery into the brain. The mechanisms that drive the exchange 
between CSF and the brain’s interstitial fluid (ISF) are either diffusion or bulk flow. The 
distance and velocity of diffusion depend significantly on the size and mass of the 
molecules. However, bulk flow occurs over more considerable distances, and all solutes 
in the CSF move at the same rate, regardless of size (for a review see Fowler et al., 2020). 
The ependymal cells lining the ventricular system, forming the CSF-brain barrier, do not 
possess tight junctions, and small solutes appear to move freely across ISF and CSF. 
Furthermore, in recent years, CSF has been shown to move into deep brain areas along 
perivascular spaces surrounding blood vessels. The CSF-ISF exchanges by convection 
from the brain-wide perivascular networks, also called the “glymphatic” system, could 
be a highly efficient route for drug delivery (Abbott et al., 2018). 
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1.7 Outline of the Study 
Systemic drug application is the main approach of epilepsy treatment. However, the CNS 
is a particularly challenging target for drug delivery. Because the BBB is highly 
restricting the availability of drugs in the brain, only a minor fraction of systemically 
applied substances can reach its target (Pardridge, 2005). Consequently, to successfully 
suppress epileptic seizures, high drug concentrations in the systemic circulation are 
required. The systemic treatment with anti-epileptic drugs can thus be accompanied by 
severe side effects caused by off-target drug exposure. Furthermore, approximately 30% 
of patients with epilepsy are pharmaco-resistant (World Health Organization, 2006) and 
it appears that, decreased drug availability in the CNS caused by BBB mechanism can 
partly underly this drug resistance (Sharma et al., 2015). Accordingly, there is a great 
interest in developing new therapeutic strategies to improve CNS drug accessibility in 
order to suppress epileptic seizures.  
Intrathecal (IT) administration of AEDs could be a possible route to bypass the BBB and 
increase the availability of neuroactive compounds in the CNS. This study's aim was an 
Figure 1.3: Cerebrospinal Fluid 
A) Schematic diagram of cranial CSF circulation through 
ventricles, cisterns, and subarachnoid space. B) Anatomy of 
the ventricular system of a rodent brain. 
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in-depth evaluation of IT drug application in the genetic absence epilepsy rats from 
Strasbourg (GAERS) and to assess if this method is a reasonable approach to treat 
epilepsy. 
The GAERS rats generate seizures, which can be monitored as characteristic SWDs in the 
EEG and the quantification of these seizures is a precise tool for assessing the efficacy of 
antiepileptic therapy (van Luijtelaar and van Oijen, 2020). Accordingly, to analyze 
seizure occurrence in GAERS and elucidate if pharmacological treatment effectively 
suppresses SWDs, EEG recordings combined with automated seizure detection have to 
be performed. Based on the quantification of detected seizures, we1 can then test and 
compare systemic and localized drug applications in epilepsy.  
 
On the one hand, we will investigate the efficacy of two standard anti-absence drugs, VPA 
and ETX, for different application routes (i.v., i.p. and i.c.v.), on the other hand, the 
efficacy of alternative antiepileptic substances such as the neuropeptides SST and NPY, 
which do not cross the BBB, will be explored after i.c.v. application in these animals. 
Neuropeptides are endogenous neuromodulators and thus, they have the advantage 
over classical AEDs that they show antiepileptic activity at extremely low doses and are 
less affected by the elimination mechanisms of the CNS (for a review see Clynen et al., 
2014). In order to identify intracranial therapeutic concentrations of anticonvulsant 
substances, dose-response experiments will be implemented and analyzed for all 
substances. 
The distribution of drugs into the brain parenchyma after applying them into the CSF is 
highly complex, and the underlying mechanisms are controversially discussed (Fowler 
et al., 2020). To gain a closer insight into the fate of drugs after i.c.v. administration, we 
will monitor ETX distribution throughout several body compartments after utilizing 
different application methods. Furthermore, the injections of dyes can visualize the 
propagation of molecules into the brain and elucidate target areas that can be reached 
by i.c.v. applied drugs.   
 
Finally, we want to investigate the cortical surface as a potential site for localized drug 
application in absence epilepsy, as this brain region would be surgically more accessible, 
less invasive, and less restricted by size compared to the ventricular system 
                                                        
1 In accordance with usual scientific writing style the pronoun ‘we’ is used throughout the thesis when 
describing my own ideas or findings. 
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2 Materials & Methods 
2.1 Animals 
All experiments were performed following the German law on animal protection and 
approved by the Animal Care and Ethics Committee of Christian-Albrechts-Universität 
zu Kiel (CAU). In total n=139 Wistar rats of the Genetic Absence Epilepsy Rats from 
Strasbourg (GAERS) strain were used for this study. All animals used in this study were 
male rats between 6 and 9 months of age. The rats were bred and housed in the Victor-
Hensen-Haus, CAU (local animal facility) under standard laboratory conditions with free 
access to food and water, 12h light/dark cycle (light on at 6 am), and a temperature-
controlled environment. The animals were housed in groups of 3 – 4 animals until 
surgery. Rats with an implanted head-stations or drug application implants were single 
housed. For experimental sessions, the animals were moved to the Physiological 
Institute, CAU Kiel, where they stayed for a maximum of five consecutive days before 
being returned to the Victor-Hensen-Haus.  
2.2 Neural implants 
EEG-head-station  
To detect the brain signals in GAERS, custom made neural interfaces, referred to as head-
stations, were used (fig. 2.1A). Stainless-steel screws were used as epidural electrodes, 
and the neural signal acquisition involved four recoding electrode and one ground 
electrode. The recording screws had a major diameter of (1.2 mm) and were 3 mm long. 
Via an insulated stainless-steel wire (Ø 0.075 mm), the electrodes were connected to 
gold-plated sockets (model E363/0, Plastics One, USA). For each recording channel, one 
of the sockets was inserted into a 6-channel plastic pedestal (model MS363, Plastics One, 
USA). The central opening of the pedestal stayed empty, as only 5-channels were used 
for the electrophysiological recordings. The pedestal functioned during the recordings 
as an electronic interface to a 6-channel, meshed EEG cable (model 363-363, Plastics 
One, USA). Finally, in order to stabilize the head-station, a thin layer of dental cement 
(Paladur®) was put above the sockets. 
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Guide cannula for chronic implantation into the lateral ventricle  
To explore the effectiveness of intracerebroventricular (i.c.v.) pharmacotherapy, 
antiepileptic substances were administered into the lateral ventricle of GAERS by 
chronically implanted guide cannulas. The custom-made cannulas (fig. 2.1B bottom 
panel) consisted of biocompatible polyethylene tubes. For the application of dissolved 
substances, tubes with an inner diameter of 0.38 mm and an outer diameter of 1.09 mm 
(ProLiquid, Germany), were used for cannula building. The final guide cannulas 
consisted of a short (3 mm) and long (7.4 mm) part, which were separated by a ring-
shaped bulge at the outer surface of the tube. The shorter end of the cannula had a pointy 
tip, to facilitate the brain implantation and to reduce tissue damage during tissue 
penetration. The long and blunt end of the cannula was utilized to guide an injection 
needle for drug application (fig. 2.1B, top panel). Each guide cannula had a matching 
Figure 2.1: Schematic illustrations of custom-made neural implants used in this study  
A) Head-station for brain signal recordings. The top view shows the cable connector, which 
is consisting of the 6-channel pedestal. The bottom view illustrates the stainless-steel screws 
(recording electrodes) connected to gold-plated sockets and inserted to the pedestal. B) 
Guide-Cannula for chronic implantation into the lateral ventricle (bottom) plus the 
corresponding injection tube (top). C) Epidural-Cup for cortical drug application. 
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dummy made from a stainless-steel injection needle. Before surgery, the cannulas plus 
the cannula dummy were kept in 70% ethanol for sterilization. 
Epidural Cup 
In order to investigate cortical ETX application, epidural cups were implemented based 
on the method of Ludvig et al., 2009. The epidural cup (fig. 2.1C) was constructed from 
200 μl capped reaction tubes (Kisker Biotech GmbH & Co, Germany). The bottom part of 
the tube was cut to create an opening with a diameter of about 4 mm. The final height of 
the cup was 10.5 mm. The edges of the opening were sanded down and a thin layer of 
biocompatible silicone adhesive (Kwik-Cast Sealant, World Precision Instruments, USA) 
was applied. Hence, sharp edges were removed, and the dura mater was prevented from 
being damaged during surgery. Finally, a ring-shaped protrusion was created by heating 
at the outer walls of the cup. Consequently, the cup had a better grip on the dental 
cement, which was applied during the surgery to stabilize the neural implant. 
2.3 Surgical procedures  
Placement of the head-station 
Before starting the surgical procedure, the rats were intraperitoneally (i.p.) injected with 
chloral hydrate (400 mg/kg, Sigma-Aldrich, Germany) to stably anesthetize the rats over 
one to two hours (Field et al., 1993). If necessary, the anesthesia was prolonged by a 
subsequent chloral hydrate injection with 20 – 30% of the start concentration. To 
counteract the depressing effect of chloral hydrate on the cardiovascular systems, the 
rats received atropine sulfate (0.2 mg/kg, B. Braun, Germany) subcutaneously (s.c.). For 
analgesia carprofen (5 mg/kg, Rimadyl) was administered s.c., pre- and postoperatively. 
Furthermore, prilocainhydrochlorid (Xylonest) was applied locally on the skin and the 
skull’s periosteum. After full analgesia and anesthesia, which was confirmed by testing 
for the toe pinch reflex, rats were placed on a heating map and adequately fixed in a 
stereotactic frame. During surgery, the eyes of the animals were covered with protective 
ointment, to prevent them from drying out. 
A vertical incision was made in the sagittal plane between the ears and the skull was 
exposed. The periosteum was removed from the bone, so that lambda and bregma 
suture-crossings, were clearly visible. Based on these landmarks, the stereotaxic 
coordinates for the five EEG electrodes were determined and marked. At these positions, 
small holes were drilled into the skull, and ideally, the dura mater was not damaged 
during the procedure. The stainless-steel screw electrodes of the head station were fixed 
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epidurally. Two recording electrodes were placed bilaterally over the frontal cortex 
(anteroposterior (AP), +3.9; mediolateral (ML), ±2.0) and two electrodes over the 
parietal cortex (AP -6.4, ML ±4.0) (fig. 2.2A). Additionally, one ground electrode was 
implanted above the cerebellum. Finally, the head-station was fixed to the rat’s skull with 
dental cement (Paladur®). As soon as the dental cement was fully cured, the skin was 
closed around the head station using stitches. After surgery, the animals were placed into 
a new cage and monitored until fully awake and behaving normally. 
Cannula Implantation 
For animals that received i.c.v. treatment (n=79), a guide cannula was implanted 
unilaterally into the right lateral ventricle. General methods of anesthesia and analgesia 
were as described above. For the cannula implantation, a hole was drilled unilaterally at 
the position AP -0.5 and ML -1.2 (fig. 2.2A). The exposed dura was carefully pierced with 
a needle and any bleedings that occurred were immediately stopped. The guide cannula 
was then slowly lowered into the brain with the help of the stereotactic manipulator. The 
required depth of 3.5 mm was reached when the protrusion of the cannula (fig. 2.2B) 
reached the skull surface. After the cannula was fixed to the skull by dental cement and 
it was detached from the stereotactic manipulator. Finally, the cannula was closed by the 
dummy to prevent possible CSF leakage and the entry of dirt into the brain. Animals that 
underwent i.c.v. treatment combined with EEG recording received six craniotomies. In 
the case of cannula implantation without the need for brain recordings, three additional 
anchor screws were implanted in close approximation to the cannula craniotomy.  
After at least three days of recovery and 1 to 2 days before starting the EEG recordings, 
the correct placement of the cannula was tested by i.c.v. injection of 100 ng Angiotensin 
II (AGII, Sigma-Aldricht, Germany) dissolved in 5 l Ringer solution (McKinley et al., 
2003). Only the animals showing drinking behavior over 20 min after AG II injection 
were included in the study. Furthermore, a 10 % methylene blue solution was injected 
via the cannula into the brain after the animals were sacrificed. By visual inspection of 
dye distribution in the dissected brain, the correct placement of the cannula was 
confirmed. If the dye was not distributed in the ventricular system, the rats were 
excluded from analysis. However, this final test could not be performed in all rats as 
some of the animals were used for concentration or histological studies. 
(Paxinos and Watson, 2006) 
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Epidural Cup Implantation  
In n=3 animals, in addition to the electrodes, an epidural cup was implanted unilaterally 
above the primary somatosensory (S1) cortex (fig. 2.2A and B). To implant the cup a 
craniotomy with a diameter of 4.2mm was needed. Therefore, enough bone around the 
center point (AP -2.0, ML -2.0) was slowly ablated with a drill. In order to prevent brain 
swelling due to overheating of the tissue, ice-cold saline was repeatedly applied to the 
skull. Once the bone was thin enough, the remaining layer could be removed carefully 
utilizing fine forceps. It was essential that the dura mater was not injured during the 
complete procedure. The epidural cup was gently positioned on the dura and held in 
place using an alligator clamp. The gap between the cup and the bone was sealed with a 
Figure 2.2: Placement of EEG screws and neural implants 
A) The craniotomy for the epidural cup (e.d.c) is shown in light purple, whereas the 
intracerebroventricular (i.c.v) cannula placement is displayed in dark purple. The recording sites 
are indicated as dots above the frontal cortex (red) and the parietal cortex (blue). An additional 
ground electrode (black) was implanted above the cerebellum. B) Schematic representation of 
coronal sections that are relevant for localized pharmacological treatment. The rostral coronal 
section (-0.4mm) shows the implantation site for the guide cannula (purple). The more caudal 
coronal section (-2.3 mm posterior to bregma) shows the implantation site of the epidural cup 
(purple). Furthermore, the shaded areas represent brain regions that play a critical role in the 
emergence of absence seizures: RTN, nucleus reticularis thalami; VB, ventrobasal thalamus; S1Tr, 
primary somatosensory cortex, trunk region; S1BF, primary somatosensory cortex, barrel field. The 
coordinates are derived from the atlas of Paxinos and Watson (Paxinos and Watson, 2006) with 
bregma as reference. 
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low toxicity silicone adhesive (Kwik-Cast Sealant, World Precision Instruments, USA). 
After the epidural cup was fixed to the skull by dental cement, it was filled with saline, to 
protect and moisten the brain. Finally, the cup was carefully closed with its cap to 
prevent the entry of dirt. 
2.4 Recording of brain signals and seizure detection 
For video- and EEG monitoring, the animals were transferred to Phenotyper cages 
(Noldus Information Technology, Netherlands). The cages had plexiglas walls and a floor 
area of 45 cm x 45 cm. The top unit of the Phenotyper cages contains an infrared-
sensitive camera and a light system, which enables the experimenter to control the light 
conditions externally. Two Phenotyper cages were placed in one isolation boxes, of 
which two were used. Within these boxes, a constant day/night cycle was guaranteed, 
and the animals were not disturbed by external noise. The temperature in the boxes was 
continuously monitored, and regular air circulation was ensured. During the EEG 
recordings, the animals were connected to a recording cable. Therefore, a cable conduit 
was implemented into the top unit of the cages. To permit free horizontal mobility in the 
cages, the cables were tethered to an electrical swivel (Bilaney, Germany). The swivel 
was fixed to a counterbalanced arm in order to facilitate the vertical head movements of 
the rats. The EEG signals were recorded using a Neuralynx data acquisition system 
(Neuralynx, Bozeman, MT, USA). The weak electrical signal (microvolts) from the brain 
was pre-amplified via an eight channel headstage (HS-8-CNR-MDR50, Neuralynx, USA). 
Afterwards, the signals were digitized at 16 kHz and online band-pass filtered between 
0.1 and 100 Hz by the Cheetah 6.2.0 recording software. Before starting the brain 
recording the channel producing the best signal to noise ratio in the other electrodes was 
chosen visually as reference electrode. 
Data Processing and Seizure Classification   
Due to the generalized occurrence of absence seizures over the entire cortex, only one 
channel was needed for offline seizure detection. Therefore, the channel with the 
cleanest signal was identified visually using Neuroexplorer analysis software. Further 
signal processing was implemented in MATLAB.  
In a first preprocessing step, a low-pass filter (40 Hz) and a high-pass filter (5 Hz) was 
applied to the signal, as the best seizure detection results were archived in this frequency 
range. Especially artifacts due to head movements of the animals could be diminished by 
the 5 Hz high-pass filter. For seizure detection, the data was split into time intervals of 
Materials & Methods  Chapter 2 
 36 
one second. As SWD complexes in GAERS show high amplitudes and a prominent 
oscillating activity between 7 – 11 Hz in the EEG (Marescaux et al., 1992), the 
autocovariance function is a useful tool to detect epileptic activity (Rodgers et al., 2015).   
 
𝑟𝑥𝑥[𝐿] =
1
𝑁 − 𝐿
∑(𝑥𝑛+𝐿 − ?̅?)(𝑥𝑛 − ?̅?).
𝑁−𝐿
𝑛=1
 
 
Accordingly, for seizure classification the autocovariance, 𝑟𝑥𝑥[𝐿], was evaluated with a 
lag (L) of ± 250ms and computed for the one-second data segments (x). The information 
contained in the autocovariance were used as features underlying a classification model 
to categorize the segments into “ictal” and “interictal” periods. In order to choose the 
best detection model and train it, a pre-classified dataset was implemented. To this end, 
all segments of a one-hour baseline recording (3600 seconds) were categorized by the 
experimenter based on visual inspection of the EEG traces and the related 
autocovariance graphs (fig. 2.3). For classifying a segment as “ictal,” it was a requirement 
that in at least two consecutive data segments, spike and wave activity was identified. 
Finally, the segments were labeled with either a “1” for ictal or a “0” for interictal activity. 
The pre-labeled dataset was used to automatically train a selection of different 
classification models in the Matlab R2019b classification learner app. The cross-
validation method showed a predictive accuracy above 98 % for the k-nearest neighbors 
algorithm. Therefore, the classifier for seizure detection used in this study is based on 
this model.  
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The performance of the classifier was tested via a test dataset containing 600 
consecutive segments from each animal recorded in this study (n=60). The test dataset 
was classified by the described model and the experimenter. The respective results were 
compared, and a confusion matrix was created by including all true positive (TP), false 
positive (FP), true negative (TN) and false negative (FN) classifications. These values 
were used to compute the overall accuracy, recall, and precision of automated seizure 
detection: 
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝐹𝑃 + 𝑇𝑁 + 𝐹𝑁
 
 
 
 
Figure 2.3: Seizure detection using autocovariance  
The EEG signal (black trace) form a GAERS rat shows a recording from one 
channel over 10 seconds containing one SWD complex. The green trace shows 
the corresponding autocovariance plots. A five-second burst of spontaneous 
SWD was detected by the implemented classifier (red highlighted), whereas 
during the pre-classification by the experimenter, six-seconds of epileptic 
activity were detected (bottom numbers: ictal = 1, interictal = 2). Hence for this 
10 second data segment, the classifier shows an accuracy of 90 %.   
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                               𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (𝑖𝑐𝑡𝑎𝑙) =
𝑇𝑃
(𝑇𝑃+𝐹𝑃)
                𝑅𝑒𝑐𝑎𝑙𝑙 (𝑖𝑐𝑡𝑎𝑙) =
𝑇𝑃
(𝑇𝑃+𝐹𝑁)
 
 
                       𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (𝑖𝑛𝑡𝑒𝑟𝑖𝑐𝑡𝑎𝑙) =
𝑇𝑁
(𝑇𝑁+𝐹𝑃)
         𝑅𝑒𝑐𝑎𝑙𝑙 (𝑖𝑛𝑡𝑒𝑟𝑖𝑐𝑡𝑎𝑙) =
𝑇𝑃
(𝑇𝑁+𝐹𝑁)
  
 
In order to have a better metric to evaluate an imbalanced dataset the F-Score, which 
considers recall and the precision was additionally computed. 
 
𝐹 − 𝑆𝑐𝑜𝑟𝑒(𝑖𝑐𝑡𝑎𝑙) = 2 ×
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 × 𝑅𝑒𝑐𝑎𝑙𝑙
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙
 
 
All animals with an accuracy below 97 % were excluded from the analysis. 
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2.5 Drug application and analysis of therapeutic efficacy 
 
Table 1: Pharmacotherapeutics used in this study 
Pharmacotherapeutics 
 
Provider 
 
Application method 
 
Reference 
  i.p. i.v. i.c.v. e.p.c.  
Ethosuximide (ETX) 
 Sigma-Aldrich Biochemie GmbH, 
Hamburg, Germany 
 
+ + + + 
 (Marescaux et al., 
1992) 
Valproic acid sodium 
salt (VPA) 
 Sigma-Aldrich Biochemie GmbH, 
Hamburg, Germany 
 
+ - + - 
 (Marescaux et al., 
1992) 
Neuropetide Y (NPY) 
 Sigma-Aldrich Biochemie GmbH, 
Hamburg, Germany 
 
- - + - 
 (Stroud et al.,2005; 
Morris et al., 2007) 
Somatostatin (SST) 
 Sigma-Aldrich Biochemie GmbH, 
Hamburg, Germany 
 
- - + - 
 (Mazarati and 
Telegdy, 1992) 
Chloral Hydrate 
 
Carl Roth GmbH + Co. KG 
 
+ - - - 
 
(Field et al., 1993) 
 
Baseline recording  
For habituation, the animals were placed into the experimental cages and connected to 
the recording cables at least five hours before starting the experiment. During all 
experiments, the animals had access to food and water ad libitum. For the baseline 
recordings, the rats were continuously video- and EEG recorded for 12  
(from 6 pm – 6 am next day, n=60) or 24 hours (from 6 pm – 6 pm next day, n=5) without 
any disturbance. All animals shown in this experimental study underwent one baseline 
recording. 
Systemic treatment of seizures  
Within this study, the systemic anti-epileptic effect of three substances (tab. 1) was 
tested. To this end, the rats were i.p. injected with these pharmaceuticals. All substances 
were dissolved in saline before administration. Animals that only received systemic 
treatment were solely implanted with a head-station for EEG recordings.  
For systemic drug testing, rats underwent two treatment sessions on two consecutive 
days. Immediately after each treatment, around 6 pm, the video monitoring and EEG 
recordings started for either 12h or 24h. The first experimental day served as a control 
session, and the animals were solely treated with i.p. ringer solution in the exact same 
way as in the experimental session. On the second day, the experimental session, the 
GAERS were i.p. injected with the substance of interest. For each substance, one dose 
Materials & Methods  Chapter 2 
 40 
was tested (tab. 2). Some animals (n=6) in this study, were systemically treated with VPA 
as well as ETX, however in between i.p. injection with the respective drug, there was a 
wash-out-phase of at least one week. 
Intracerebroventricular treatment of seizures 
The efficiency of localized drug therapy was investigated on the basis of 
intracerebroventricular (i.c.v.) treatment in GAERS using four potential antiepileptic 
substances (tab. 1). The animals that received i.c.v. treatment were implanted with a 
head-station and an i.c.v. cannula (fig. 2.2). The correct placement of the cannula was 
confirmed before starting the experiments by AGII injection (cf. Chapter 2.3). The 
substances of interest were dissolved in saline before administration. In order to test 
substances and the application method, rats underwent two treatment sessions on two 
consecutive days. Immediately after each treatment, around 6 pm, the video monitoring 
and EEG recordings started for 12 hours. The first experimental day served as a control 
session, and animals were treated only with ringer solution i.c.v. On the second day, the 
experimental session, the GAERS were i.c.v. injected with the substance of interest. For 
the i.c.v. administration, a constant volume of 20 l (ETX, VPA) or 2 l (NPY, SST) was 
injected. The injection needle connected to a polyethylene tube, plus Hamilton syringe 
was carefully inserted into the guide cannula, and the fluid was slowly injected (fig. 2.1). 
During the injection, the animals were handled by the experimenter. After removing the 
injection cannula, the guide cannula was closed again with the dummy. For all 
substances, several concentrations were tested (tab. 2). The animals were treated 
repeatedly with different substances and doses. The wash-out-interval between tests 
was at least one week. 
Epidural treatment of seizures with ETX 
In order to investigate the potential of epidural drug applications, ETX was directly 
applied to the S1 cortical surface in three animals. Animals that received epidural 
treatment were implanted with a head-station and an epidural cup (fig. 2.1). For the 
investigation of this application method, rats underwent two treatment sessions on two 
consecutive days. Immediately after each treatment, around 6 pm, the video monitoring 
and EEG recordings started for 12 h. The first experimental day served as a control 
session. To this end the epidural cup was filled with 20 l ringer solution. On the second 
day, the cup was filled with ETX dissolved in 20 l ringer solution.  
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During the treatment, the animals were handled by one experimenter while another 
person was carefully pipetting the solution into the center of the cup as close to the brain 
surface as possible. All animals were treated with two drug doses (tab. 2). In between 
the experimental trials, a wash-out-phase for ETX of at least one week was observed. 
 
 
  
Table 2 : Study design for substance application combined with EEG recordings   
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Within animal comparison of different ETX administration routes  
In a final experiment, the effectiveness of three different administration routes was 
compared directly, in one cohort of eight animals. The different application methods 
used in this experiment were intraperitoneal (i.p.) injections, intravenous (i.v.) 
injections into the tail vein and intracerebroventricular (i.c.v.) injection. The different 
treatments were performed in three experimental trials in three consecutive weeks. The 
animals received in each case an ETX dose of 2mg per animal. The GAERS used in this 
experiment were implanted with a head-station and an i.c.v. cannula.  
Each experimental trial consisted of two treatment sessions on two consecutive days. 
Immediately after each treatment, around 6 pm, the video monitoring and EEG 
recordings started for 12 hours. The first day was a control session, where animals were 
treated with ringer solutions via the same application route as in the subsequent 
experimental session. However, in order to prevent clotting of the vein during the i.v. 
trial, a sham control (no ringer injection) was performed. On the second day GAERS, 
were treated with ETX. For i.c.v. treatment, a constant volume of 20 l was injected 
whereas during i.v. and i.p. treatment an injection volume of 0.1 ml was used (tab. 3).  
 
  
Table 3: Study design for within animal comparison of different ETX administration routes combined 
with EEG recordings .  
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2.6 Analysis of ETX distribution throughout different body 
compartments after i.c.v. and systemic administration 
The ETX concentration was quantified in the blood plasma, brain tissue, and the CSF after 
application in order to understand the distribution dynamics of this drug. The ETX 
concentration measurement was performed for three groups of animals which received 
different types of treatment: 
In the first group, including five non-operated animals, the samples were collected one 
hour after i.p. treatment with the therapeutic concentration of ETX (100 mg/kg). In a 
second group, the drug distribution was determined after i.c.v. therapy. The animals that 
received ETX via i.c.v. injection underwent cannula implantation one week before 
sample collection. One day before ETX treatment, the animals were i.c.v. injected with 
AGII to confirm correct cannula placement. For the sample collection, all animals (n=12) 
were i.c.v. treated with an ETX dose of 2 mg per animal. In order to further analyze a 
time-dependent drug distribution, the samples were collected 15 minutes (n=4), one 
hour (n=4), and four hours (n=4) after ETX injection. In the final group, including 12 non 
operated rats, the samples were collected after i.v. injection of 2 mg per animal ETX. The 
samples were collected 15 minutes (n=4), one hour (n=4), and four hours (n=4) after 
ETX injection. To have reference samples for the HPLC analysis in each group, one animal 
received only a vehicle injection, and one additional animal received no treatment at all.   
CSF Collection   
The CSF was collected from the cisterna magna employing a cisternal puncture 
technique (Li et al., 2016). During CSF sampling, the animal was deeply anesthetized with 
chloral hydrate (400 mg/kg). After confirming anesthesia, the rat was placed in a 
stereotactic frame and the head was fixed in a flexed position, with the nose pointing 
downward. The puncture site of the cisterna magna is located between the occipital 
protuberance and the atlas, which was felt as a depressive spot at the back of the head. 
Next, a 25G infusion needle attached to a polyethylene tubing was carefully inserted 
centrally into the atlanto-occipital membrane until a “give” was felt. After gentle 
aspiration, CSF started flowing, and around 20 – 100 l CSF was collected. The color of 
the CSF was closely observed to avoid blood contamination. The CSF was immediately 
put on ice and until further analysis stored at -80C.  
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Blood Plasma collection  
Following the CSF collection, a cardiac puncture technique was used to acquire blood 
plasma samples (Sharp and Villano, 2012). After the rat received a lethal dose of chloral 
hydrate, it was placed on its back. A 21G cannula attached to a syringe was inserted 
underneath the rips at a 30° angle slightly left of the sternum. As soon as the needle 
entered the heart, 1ml of blood was collected in heparinized tubes (Microvette® 500, 
Sarstedt). The heparinized blood samples were centrifuged at 2.000 x g for 15min. After 
centrifugation, the supernatant, respectively, the plasma was carefully collected in an 
Eppendorf® tube. The plasma was until further analysis stored at -80°C. 
Brain tissue collection  
Immediately after the plasma and CSF samples were collected, the brain of the animal 
was surgically removed. In order to wash away the extraneous blood, the brain was 
rinsed in ice-cold PBS and thereafter placed dorsoventrally onto an ice-cold brain matrix 
(model RBMS-300C, World Precision Instruments, USA). In order to dissect specific brain 
regions, a coronal brain slice between -1 mm to -3 mm in relation to bregma was 
collected. The brain slice was put on an ice-cold metal block and further dissected. Based 
on the visual identification of anatomical landmarks, brain regions of interest were 
isolated. The brain areas of particular interest were the thalamus and the somatosensory 
cortex from both hemispheres. The coordinates were based on the matrix-guided 
trimming protocol of Defazio et al. (2015). 
The brain samples were collected in Eppendorf® tubes and weighted. For each sample, 
twice the volume of cold ultrapure water was added to the tube, and the collected brain 
tissue was homogenized by grinding (B.Braun, Germany). Next, the homogenized 
samples were centrifuged at 16.000 x g for 15min. After centrifugation, the supernatant 
was carefully collected and stored at -80°C for further analysis.  
The following formula was used to calculate the final ETX concentration (CF) in the brain 
tissue:  
 
𝐶𝐹(µg/𝑔) =
(𝐶𝐷 ∗ 𝑉𝐷)
𝑊
 
 
where CD is the measured drug concentration (µg/mL), VD the volume of added ultrapure 
water (mL) and W the weight of the brain sample (g). 
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HPLC analysis 
In cooperation with Prof. Dr. Regina Scherließ and Hanna Göttsche at the Institute of 
Pharmacy, CAU Kiel, the ETX concentration in the different specimens (blood plasma, 
CSF, and brain samples) was quantified by high-performance liquid chromatography 
(HPLC, Waters Corporation, Milford, USA) following UV detection. The mobile phase for 
the HPLC procedure was composed of 90 % ddH2O (the pH was adjusted to 2.2 by 
H3PO4) and 10 % acetonitrile and had a constant flow rate of 1.0 ml/min. In order to 
separate the analyte, a LiChro- CART® 125-4 LiChrospher® 100 RP-18 (5 μm) column 
combined with a pre-column (Merck KGaA, Darmstadt, Germany) was used. The column 
temperature was set to 50°C. A volume of 10 l was injected into the apparatus, and the 
detection wavelength was set to 205 nm (detector PDA 2998). The calibration curve for 
ETX was linear over the concentration range of 0.055–156.0 μg/ml. 
Fast green diffusion test 
After i.c.v. administration, the pharmacotherapeutics must penetrate through the brain’s 
extracellular space and reach specific target areas to show antiepileptic efficacy. In 
absence epilepsy, the S1 cortex and the thalamus are of particular interest (Meeren et al., 
2005). In order to visualize substance penetration into the brain tissue, the dye fast 
green (FG; Merck) was i.c.v. injected in three rats. Prior to the i.c.v. administration of 2 % 
FG (dissolved in ringer solution), the animals were deeply anesthetized with chloral 
hydrate (400 mg/kg). If necessary, the anesthesia was prolonged by a subsequent chloral 
hydrate injection with 30 % of the start concentration. A constant injection volume of 20 
μl FG was used. In order to further analyze a time-dependent drug distribution, animals 
were killed either 5 min (n=1), one hour (n=1), or four hours (n=1) after FG injection. 
After the respective time was elapsed, the rats were euthanized with a lethal dose of 
chloral hydrate. The animals were immediately decapitated, and the brains were 
surgically removed from the skull. In an ethanol/dry ice bath, the brains were shock-
frozen and embedded in OCT. Until sectioning, the brains were stored at -80°C. Brains 
were cut into 80 μm thick coronal sections on a Leica CM 3050S cryostat 
(RRID:SCR_016844). To see the dye distribution more clearly digital photographs were 
taken directly from the embedded brain in the block. 
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2.7 Neurotoxicity tests  
Behavior 
To determine if the intracerebroventricular injections of ETX causes adverse effects in 
GAERS several behavioral tests were performed. For the Irwin test (Honack and Löscher, 
1995) animals were placed in an open field (OF) and observed for ten minutes 
consecutively. Attention was paid to abnormal behavior such as hyperlocomotion, 
sedation, ataxia, head swaying, circling, stereotypic sniffing, hypermetric gait, wet dog 
shakes and, flat body posture. The observations on behavioral abnormalities were 
scored as described in table 4.  
Furthermore, the responses to external stimuli were tested utilizing the 
hyperexcitability test (HET) (Rice et al., 1998). The HET consists of four different test 
sessions. The first session was an “approach-response test”, consisting of a pen slowly 
moving towards the rat’s nose. In a direct follow up session, respectively the “touch-
response test” the rat was carefully touched with the same pen at the rump. During the 
“finger-snap test” a clicking noise was generated a few centimeters above the animal’s 
head. Finally, the rat was picked up by grasping it around the rump which is called the 
“pick-up test”. For all tests the animal’s reactions were observed closely and scored as 
describe in table 4. 
The motor coordination was analyzed using the RotaRod test (Dunham and Miya, 1957; 
Tollner et al., 2011). To pass this test, animals had to balance on a rotating rod (Ø 7.5; 8 
rpm) without falling off for at least 2 min in one of three trials.  
Experimental Setup 
Two days before starting the behavioral experiments, animals were habituated with the 
different test procedures. The animals were tested once without any treatment, one day 
after i.c.v. application of ringer solution, and one day after i.c.v. treatment with ETX (0.3 
mg, 0.6 mg, 1.2 mg, 2.0mg, 2.5 mg; n=5). Hence the animals were undergoing all tests 
(OF-, HET- und Rotarod-Test) within a period of five consecutive days. Furthermore, the 
bodyweight of the animals was taken at each day of behavioral testing. The tests were 
always performed at 5 pm i.e., one hour before starting the next treatment.  
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Table 4: Selected Tests to Assess Behavioral Impairment caused by i.c.v. applied ETX   
Test  Parameters  Score  
 
 
Open Field-Test 
(OF) 
(Honack and Löscher, 1995) 
 Hyperlocomotion / Sedation 
Ataxia 
Head Swaying 
Circling  
Stereotypic Sniffing 
Hypermetric Gait  
Wet Dog Shakes  
Flat Body Posture 
 0 - absent  
1 - equivocal 
2 - present  
3 - intense  
 
 
 
 
 
 
 
 
 
Hyperexcitability Test (HET) 
(Rice et al., 1998) 
 1. Approach-Response Test 
 
 1 - no reaction  
2 - the rat is sniffing at the object  
3 - the rat moves away from the object  
4 - the rat is freezing 
5 - the rat jumps away from the object 
6 - the rat attacks the object  
 2. Touch-Response Test  1 - no reaction  
2 - the rat is moving toward the object  
3 - the rat moves away from the object  
4 - the rat is freezing 
5 - the rat is moving toward the touch 
6 - the rat is moving away from the touch  
7 - the rat jumps away with or without 
vocalization   
 3. Finger-Snap Test  1 - no reaction  
2 - the rat jumps slightly (normal reaction) 
3 - the rat jumps dramatically  
 4. Pick-Up Test  1 - very easy 
2 - easy with vocalization   
3 - more difficult, the rat rears and faces the 
hand 
4 - the rat is freezing 
5 - difficult, the rat is avoiding the hand 
6 - very difficult, the rat behaves 
defensively, and may attack the hand 
 
Rotarod-Test 
(Dunham and Miya, 1957) 
 
 2 min on a rotating rod  Test passed at the 1
st, 2nd or 3rd trial 
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2.8 Data analysis and statistics  
In order to evaluate the epileptic activity in GAERS, three parameters were analyzed 
after seizure detection: the cumulative time in SWDs, the number of epileptic incidences, 
and the mean duration of the individual seizures. To assess time depended changes of 
epileptic activity after treatment, line graphs were plotted to display quantitative values 
of the distinct parameter within one-hour bins over the entire time of recording. To 
quantify the change of epileptic activity after drug application in a direct within-animal 
comparison, the percentage of control was computed for each animal individually. 
 
 
percentage of control =
𝐸𝑝𝑖𝑙𝑒𝑝𝑡𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 
𝐸𝑝𝑖𝑙𝑒𝑝𝑡𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑎𝑓𝑡𝑒𝑟 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛
∗ 100 
 
 
However, as percentage of control and the control value (epileptic activity after vehicle 
injection) are mathematically coupled, the statistical analysis between these two values 
could be misleading (Tu, 2016). Therefore, all the statistical tests reported in this thesis 
were performed on the averaged group data per hour computed over a time window of 
interest (12 h, 5 h, or 2 h) compared to the control group. 
 
The data was statistically analyzed using the GraphPad Prism 8 Software (Graph-Pad 
Software, San Diego, CA, USA). The D’Agostino-Pearson test was used to determine if the 
data were normally distributed. For all data, a parametric test could be used. Drug effects 
were assessed by repeated-measures analysis of a one-way analysis of variances 
(ANOVA) or a two-way ANOVA, followed by post-hoc testing for individual differences 
with the Tukey’s test.  The data were presented as mean ± stand error of the mean (SEM). 
Statistically significant differences are highlighted by asterisks depending on the p-
value: (*)P ≤ 0.05, (**) P ≤ 0.01,(***) P ≤ 0.001, (****) P ≤ 0.0001. 
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3 Results  
In 25 – 30 % of people diagnosed with epilepsy, seizures cannot be effectively 
suppressed with standard pharmacotherapy (World Health Organization, 2006). A 
general problem of systemic drug therapies of brain diseases is the limited permeability 
of the blood-brain-barrier (BBB), which is restricting the accessibility of the central 
nervous system (CNS) for many drugs. It thus remains challenging to reach therapeutic 
drug concentrations at the desired site of action. Accordingly, there is great interest in 
developing new therapeutic strategies to improve CNS drug accessibility and control 
brain diseases like epilepsy. In this study, the potential of localized pharmacotherapy 
was investigated. To this end, the effect of intracerebral drug application was explored 
in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS).  
3.1 EEG-based analysis of seizure activity in GAERS 
GAERS represent one of the best-established models for generalized epilepsy and the 
pathological neuronal activity underlying the epileptic seizures have been described in 
detail by Marescaux et al. (1992). The quantification of this epileptic activity is a 
particularly precise tool for assessing the efficacy of antiepileptic therapy. Therefore, it 
was essential to establish high-quality EEG recordings in our laboratory and compare 
patterns of pathological activity with those reported in the literature, to implement 
efficient seizure detection in GAERS.  
Analysis of EEG signals revealed clean phase-locked oscillations consisting of a spike 
followed by a slow wave, with spike amplitudes ranging between 0.2 and 1.2 mV  
(fig. 3.1), resembling those previously described for this model in the literature  
(Danober et al., 1998). The distinct morphology of the spike-and-wave discharges 
(SWDs) was consistent over all epileptic events. However, there was variability in the 
duration of seizures episodes: some events comprised only a few spikes, whereas others 
lasted for several minutes (fig. 3.1A). Both seizure onset and termination were abrupt, 
and during interictal phases, the animals showed regular brain activity. The spectrogram 
of SWDs displayed nearly horizontal energy ridges indicating a harmonic structure of 
the signal (fig. 3.1B).  
The fundamental frequency, which describes the first harmonic, was detected around 
~7 Hz in the power spectrum and the spectrogram (fig. 3.1B and D). These findings agree 
with the key observation that SWDs are a quasi-periodic signal (Hese et al., 2003).  
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The autocovariance is strongly related to the spectral analysis and is thus a useful tool 
to assess rhythmic activity, such as SWDs, in EEG data (fig. 3.1C)(Rodgers et al., 2015). 
The autocovariance plot shows two repeating peaks varying in amplitude and phase (fig. 
3.1C). The flatter curve corresponds to the wave complex; the higher peak corresponds 
to the spike complex. Both peaks appear approximately every 0.14 s, which again reflects 
the fundamental 7 Hz SWD-frequency and its harmonics. Thus, the autocovariance 
reflects amplitude, frequency, and the morphology of SWD complexes.   
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Figure 3.1: EEG recordings and analysis of epileptic activity in GAERS  
A) Example EEG recording showing several SWD epochs. The characteristic morphology of the SWDs 
remains constant over, within, and between individual epochs. However, the duration of SWD epochs 
shows variability. B) The upper trace shows a 75 s EEG fragment containing four SWD epochs. Below 
the EEG, the corresponding spectrogram is displayed. The spectrogram highlights the intense 
rhythmic activity and harmonic patterns of the SWDs. C) The black trace shows two SWD complexes 
with the corresponding scaled and superimposed autocovariance function (red trace). The typical 
“spike“ and “wave“ complexes in the EEG recording, which are characteristic for absence seizures, 
are highlighted. D) The power spectrum of a five-second SWD epoch, displaying the fundamental 
frequency of ~7 Hz and its harmonics.    
 
Results  Chapter 3 
 52 
3.2 Automated detection of SWDs in the cortical EEG of GAERS 
The automated detection of SWDs would allow fast and consistent quantification of 
seizures in GAERS. The EEG recordings showed prominent features of SWDs based on 
amplitude, frequency, and waveform morphology (fig. 3.1), representing ideal 
conditions for implementing an automated seizure classification system. Therefore, a 
classifier was trained in MATLAB on a dataset of 3600 seconds of EEG recordings with 
the computed autocovariance that was used as feature vector. The thereby implemented 
classifier was then applied to a test dataset in order to assess its performance. The test 
dataset consisted of a 36000-second-long EEG recording from GAERS (fused 10-minute 
datasets from each animal recorded within this study). This dataset had been pre-
classified into “ictal” and “interictal” events by visual inspection. Visual inspection 
revealed that the animals spend approximately 10 % of the recorded time in seizures 
since 32662 seconds were classified as “interictal” and only 3338 seconds as “ictal”  
(fig. 3.2B). Furthermore, this counting showed that the dataset was imbalanced, which is 
essential to note when assessing the classifier’s performance (Sun et al., 2009). An 
imbalanced dataset is characterized as having many more instances of one class (in our 
case, “interictal” events) compared to the other class (“ictal” events). 
The confusion matrix visualizes the performance of automated seizure detection by 
presenting all false positive (orange), false negative (red), true positive (blue) and true 
negative (white) classifications (fig. 3.2). An exemplary performance analysis, tested on 
one animal, is shown in figure 3.2A. Highlighted detection errors in the EEG plot 
demonstrated that most false classifications occur either at the beginning or the end of a 
seizure.  
The final evaluation of automated seizure detection over the complete test dataset, with 
the corresponding confusion matrix and accuracy, is shown in figure 3.2B. The confusion 
matrix reflected a relatively low and even number of false positive and false negative 
detections. The classifier showed an overall accuracy above 99 %; however, as the 
dataset was imbalanced, the accuracy measure could be a misleading metric to evaluate 
the performance of classification (Sun et al., 2009). Accordingly, we also analyzed the F-
Score. The F-Score considers both the recall and the precision of “ictal” events and is 
consequently a more realistic measure of the SWD detection performance. Recall 
denotes the proportion of actual ictal or interictal events that were retrieved correctly, 
while precision denotes the proportion of retrieved ictal or interictal events that were 
identified correctly. The F-Score for ictal events was above 95 %, which was considered 
adequate for the purpose of this study. 
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Figure 3.2: Performance of automated seizure detection in GAERS 
A) The left panel shows a 10 minutes long EEG recording (dark blue line) from one GAERS rat. Each 
second in the recording was classified either as “ictal” or “interictal” by both the experimenter and 
the automated seizure detection. The blue marked time windows represent correctly identified 
“ictal” events by the implemented classifier (true positive classification). Brain activity with no 
colored background indicates correctly classified “interictal” events (true negative classification). 
The EEG marked orange represents time sections that were incorrectly classified as “ictal” (false 
positive classification). The red time windows show incorrectly classified “interictal” events by 
automated detection (false negative classification). Interestingly false predictions appear always 
at the end or beginning of a seizure. The right panel shows the corresponding confusion matrix and 
the computed accuracy of the implemented classifier. B) The final performance of automated 
seizure detection, used in this study, is visualized via a confusion matrix (left panel). In order to 
better evaluate the performance of the classifier, precision and recall were also computed for 
“ictal” and “interictal” periods (middle panel). The accuracy measurement takes all values from the 
confusion matrix into account, whereas the F-score for ictal events considers recall and precision 
(right panel). 
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3.3 The circadian dynamics of spike and wave discharge 
It has been shown that the vigilance level of GAERS strongly influences the occurrence 
of epileptic activity (Lannes et al., 1988). Therefore, it is essential to decouple the 
circadian dynamics underlying seizure occurrence from antiepileptic drug efficacy 
testing during the experimental phase. To examine the circadian dynamics of seizure 
activity in GAERS under drug-free conditions, all baseline recordings performed in this 
study were combined. The cumulative time in SWDs (fig. 3.3A), the number of SWDs  
(fig. 3.3B; green), and the mean duration of SWDs (fig. 3.3B; pink) were analyzed over 12 
or 24h in one-hour bins. 
As expected, we found that the cumulative time animals spend in seizures showed 
dynamics that closely followed the circadian rhythm (Van Luijtelaar and Coenen, 1988). 
Elevated and stable seizure activity during the first seven hours of the dark phase was 
followed by a noticeable increase of SWD activity between 1 pm and 4 pm, which was 
again followed by a steep drop in seizure activity towards the end of the dark phase  
(fig. 3.3A). In general, seizure activity was slightly decreased during the light phase; 
however, the cumulative time in seizures increased again towards the end of the day. It 
is of interest to note that 46 of the individual recordings were performed during the 12 
hours of the dark phase (6 pm – 6 am), whereas only an additional 15 animals were 
recorded over 24h (6 pm – 6 pm). This explains a higher variability in seizure occurrence 
during the light phase (fig. 3.3).  
The cumulative seizure duration is a composite of the incidences and the mean duration 
of SWDs (fig. 3.3B). The number of SWDs stayed almost stable over the complete 24h 
with 29.35 ± 0.72 (mean ± SEM) of SWD incidences per hour. Only at the end of the dark 
period, during deep slow-wave sleep (Van Luijtelaar and Coenen, 1984), the number of 
seizures dropped noticeably to 22.3 ± 1.65 (mean ± SEM) seizures per hour. The 
variation of the mean duration of SWDs over time more closely followed the described 
dynamics of total time spend in seizures. Particularly notable is the peak after 10 hours 
in the dark period, showing an individual seizure length of 15.15 ± 0.50s (mean ± SEM) 
followed by a drop of more than six seconds between 5 am and 6 am.   
Baseline recordings showed that the epileptic activity is highly dependent on the sleep-
wake states of the animals. Hence drug efficacy was always tested at the same time of 
day to control circadian effects. In the first few hours of the dark period, we observed a 
high incidence of SWDs and stable seizure activity; consequently, we chose to test for 
antiepileptic drug effects during this time period.   
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Figure 3.3: SWD activity follows a circadian rhythm  
A) The black line shows the temporal dynamics of the cumulative duration 
GAERS spent in seizures over 24h under drug-free conditions in one-hour 
bins. All baseline recordings performed in this study were included (graphs 
show mean ± SEM, Night: n=61, Day: n=15). Note the peak of cumulative 
time in SWDs between 3 pm and 4 pm, followed by a steep drop at the end 
of the dark phase. B) The number of SWDs is shown in green; the mean 
duration of SWDs is shown in pink (solid lines and symbols indicate the 
mean, shaded areas indicate ± SEM).  
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3.4 Systemic treatment of GAERS with VPA and ETX 
The GAERS model has a nearly identical therapeutic profile as human absence epilepsy, 
and classical AEDs such as VPA and ETX show systemically good anti-absence efficacy at 
the therapeutic dose (Marescaux et al., 1992). To analyze and compare the antiepileptic 
activity of VPA and ETX in more detail, the therapeutic response was evaluated over a 
time course of 12 or 24h after systemic (i.p.) drug application. We analyzed the 
cumulative time of SWDs, the number of epileptic incidences, and the mean duration of 
seizures. By analyzing these different parameters, we gain insights into the mechanisms 
and brain regions controlling SWDs and can thus possibly retrace how and where seizure 
suppressing drugs exert their action. Whereas the number of SWDs is mainly determined 
by the excitability of the cortex, the mean duration is affected by different endogenous 
mechanisms involved in aborting ongoing SWDs in the thalamus (Lüttjohann and van 
Luijtelaar, 2015).  
ETX 
The intraperitoneal injection of 100 mg/kg ETX (n=7) (Marescaux et al., 1992) caused 
an immediate reduction of epileptic activity (fig. 3.4; pink trace). The reduction of SWDs 
was nearly complete during the first five hours after drug application. During the next 
four hours, the seizure activity very slowly increased. After 10 hours, the cumulative 
time of SWDs peaked, followed by a sharp drop of epileptic activity towards the end of 
the dark period. This peak's timing paralleled the endogenous rhythm of seizure 
occurrence in GAERS (cf. fig. 3.3) and was also observed in controls (n=13; fig. 3.4A). 
Consequently, for the recording time of 12 hours, the cumulative time in seizures after 
treatment was significantly lower (p=0.0003) than in the controls. All statistical tests 
reported in this manuscript were performed on the absolute values (average per hour) 
of the three parameters within a specific time window (here 12 hours) 
(fig. 3.4; middle panels).  
To better quantify the reduction of epileptic activity after drug application and to 
consider inter-individual differences of GAERS, the percentage of control was computed 
for each animal individually (fig. 3.4; right panels). On average, the systemic treatment, 
with the therapeutic dose of ETX (100 mg/kg), reduced the cumulative time in seizures 
by 86.47 ± 2.8 % (mean ± SEM) compared to vehicle injection over the complete 12h of 
recording. 
The temporal dynamics are strikingly similar for cumulative time in seizures and the 
number of SWDs (fig. 3.4A and B), which could indicate that the decreased number of 
seizures can, to a large extent, explain the antiepileptic effect of ETX. Over the first nine 
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hours only a few seizures are evident followed by a peak in seizure number after 10 
hours and a subsequent drop of seizures towards the end of the dark phase  
(fig. 3.4B; left panel). Furthermore, over the complete 12 hours the number of SWDs is 
decreased by approximately 86.81 ± 2.0 % (mean ± SEM) after ETX treatment compared 
to vehicle injection, which coincides with the percentage of change shown for cumulative 
time in seizures (fig. 3.4A and B; right panel). Accordingly, the number of seizure 
incidences after treatment was significantly lower (p = <0,0001) than in the controls 
(fig. 3.4B; middle panel). 
Systemically applied ETX effects the mean duration of SWDs differently compared to the 
number of epileptic incidents (fig. 3.4C). After drug application, during the first five 
hours, the mean duration of SWDs is reduced compared to vehicle injection. However, it 
is important to note that, on average less than one seizure occurs per hour during this 
period of time. Therefore, the mean duration was computed over a small number of 
epileptic incidences and can be considered inconclusive. Six hours after ETX treatment, 
the mean duration of SWDs has completely recovered, and no differences between the 
control and the experimental group are visible (fig. 3.4C; left panel). Consequently, for 
the recording time of 12h, no significant difference could be identified for the mean 
duration of SWDs between ETX and vehicle injection (p = 0.44) (fig. 3.4C; middle panel). 
 
To evaluate if the therapeutic efficacy of ETX exceeds the described 12 hours, five 
additional animals were i.p. injected with the therapeutic concentration of the AED  
(100 mg/kg) and recorded for 24 hours (fig. 3.5). The cumulative duration of SWDs 
shown in figure 3.5 indicates that the seizure reducing effect did not persist beyond the 
first 12 hours after ETX application. 
VPA 
The systemic treatment with the therapeutic concentration of 200 mg/kg VPA (n=6) 
(Marescaux et al., 1992) resulted in an immediate and nearly complete reduction of 
seizure activity in GAERS (fig. 3.4; green trace). However, already three hours after VPA 
treatment, a steep increase of the cumulative duration of SWDs is visible. Consequently, 
when compared to the control experiment, no difference in cumulative SWD duration 
was obvious (p = 0.64). Similarly, mean seizure duration and the number of seizures 
dropped at the beginning of the recording and quickly recovered after about two hours 
(fig. 3.4B and C). As the antiepileptic efficacy of VPA only lasted two hours after 
treatment, none of these parameters showed a statistically significant change compared 
to the control experiments over the 12h recording period.   
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Figure 3.4: Epileptic activity in GAERS during the first 12 hours following systemic 
treatment with VPA or ETX 
The analysis of epileptic activity is divided into A) the cumulative duration in SWDs, B) the 
number of SWDs, C) the mean duration of SWDs. The left panels show the time course of 
the respective parameter over 12h (one-hour bins) after systemic treatment with the 
therapeutic dose of either VPA (green; n=6) or ETX (pink; n=7) (solid lines and symbols 
indicate the mean, shaded areas indicate ± SEM). The bar plots in the middle panels display 
the average/hour (± SEM) of the distinct parameter computed over the complete 12 hours 
of recording. The right panels show the analysis of the percentage of control within 
animals, with dots representing individual animals. The statistical analysis was performed 
by one-way ANOVA with Tukey’s post-hoc test. (**) P ≤ 0.01,(***) P ≤ 0.001, (****) P ≤ 
0.0001. 
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Comparison of systemic treatments with ETX and VPA showed longer antiepileptic 
efficacy for ETX, in accordance with the pharmacokinetics (e.g., half-life and clearance) 
of the respective drugs (cf. Chapter 1.4 and Löscher, 2007). Considering the entire 12 h 
after drug application, the systemic treatment with ETX was significantly more efficient 
in reducing cumulative time in SWDs (p = 0.004) and the number of seizures 
(p = 0.0003) than VPA. 
  
Figure 3.5: Epileptic activity in GAERS after systemic treatment with ETX over 
24 hours  
The time graph shows the cumulative duration of SWDs over 24h in one-hour bins 
after systemic treatment with the therapeutic dose of ETX (pink; n=5). The control 
recordings (black; n=5) show the cumulative duration in SWDs after vehicle 
injection (solid lines and symbols indicate the mean, shaded areas indicate ± SEM). 
Over the first 11h, GAERS show the expected reduction in SWDs, but the seizure 
reducing effect did not persist beyond 12h. 
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3.5 Intrathecal treatment of GAERS with VPA and ETX  
Two key areas involved in initiation and propagation of absence seizures are the 
somatosensory cortex and the dorsal thalamus (for a review see Meeren et al., 2005), 
which both lay in proximity to the ventricular system. Thus, we reasoned that i.c.v. 
injections of antiepileptic drugs might represent an efficient route of drug application, 
bypassing the blood-brain-barrier (BBB) (cf. fig. 2.2). Therefore, we implanted guide 
cannulas into the right lateral ventricle and gauged the effectiveness of ETX (fig. 3.6) and 
VPA (fig. 3.7) for intracranial applications. To find therapeutic concentrations, a dose-
response experiment was performed using doses between 0.3 and 2.5 mg for both drugs. 
 
Unilateral i.c.v. application of ETX 
Modulated onto the time course, we observed a dose-dependent reduction of SWDs 
between 1.2 mg and 2.5 mg but not for 0.3 mg or 0.6 mg ETX. The onset of the 
anticonvulsant effect showed a time delay of 1 to 3 hours and lasted between 4 – 5 hours 
with some variability (fig. 3.6A; left panel).  
To take into account the limited duration of the anticonvulsant activity, we evaluated in 
more detail the therapeutic effect of the different ETX doses for the five consecutive 
hours showing the most robust decrease in epileptic activity. The five-hour time-window 
was chosen based on the visual inspection of SWD dynamics over time (fig. 3.6; left 
panels) and on our finding of the pharmacokinetics of ETX after systemic treatment 
(fig. 3.4; pink trace). The most effective time window – termed “best five hours” from 
now on – was determined via a sliding window separately for each animal, as we 
observed intraindividual variability. On average, the best five hours started after 1.9 
hours.  
 
The statistical analysis and the within animal percentage of control for all parameters 
were based on these best five hours after ETX treatment. The dose of 0.3 mg ETX showed 
no appreciable effect, whereas 0.6 mg ETX already reduced seizure activity by 24.24 ± 
8.42 % (mean ± SEM)(fig. 3.6A; right panel), although this was statistically not significant 
different from vehicle injection (fig. 3.6A;middle panel). The dose of 2.0 mg ETX showed 
the most potent anticonvulsant effect with a reduction to 58.25 ± 6.0 % (mean ± SEM) in 
cumulative time in SWD. Based on the absolute values this was significantly different 
from the controls (p = <0.0001). Within the best five-hour time window, the treatment 
with the 2.5 mg dose induced a slightly weaker anti-absence efficiency as the treatment 
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with 2.0 mg ETX (-41.24 ± 8.38 % (mean ± SEM)). However, the absolute values showed 
still significant different between vehicle und 2.5 mg ETX injection.  
 
Indeed, even over the complete 12 hours, the time in seizures after i.c.v. treatment with 
2.0 mg ETX was significantly lower (data not shown; p=0.02) than in the controls. 
Because of a sharp increase in seizures after midnight, the highest dose of 2.5 mg ETX 
was noticeable less effective than 2 mg ETX (fig. 3.6A; left panel) over the entire 
recording time. Compared to vehicle injection, the seizure duration even slightly 
increased by 20.37 ± 25.78 % (mean ± SEM; data not shown), although this was not 
statistically significant (data not shown, p=0.92). Interestingly, the observations of an 
inverted U-shaped relation between ETX dose and seizure suppression has previously 
been reported for direct injections of ETX into the thalamus (Richards et al., 2003).  
 
Only the ETX doses which induced statistically significant seizure reduction in the rats  
– 1.2 mg, 2.0 mg, and 2.5 mg – were included in the graphs of figure 3.6B and C. Over the 
best five hours, the treatment with the most promising dose of 2.0 mg ETX evoked a 
significant decrease in both the number of SWDs (p=0.0005) and the mean duration of 
SWDs (p=< 0.0001)(fig. 3.6B and C; middle panels). Interestingly, the AED induced a 
higher percentage of change for the mean duration of SWDs  
(-36.5 ± 5.13 % (mean ± SEM)) compared to the percentage of change of seizure 
incidences (-28.1 ± 9.59 % (mean ± SEM) (fig. 3.6B and C; right panels). A similar 
outcome was observed for the i.c.v. treatment with 2.5 mg. However, the application of 
1.2 mg resulted in a significant reduction in the number of seizures (p=< 0.0001) but not 
for the mean seizure duration of SWDs (p=0.6). 
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Figure 3.6: Epileptic activity in GAERS after i.c.v. treatment with different doses of ETX  
The analysis of epileptic activity is split into A) the cumulative duration in SWDs, B) the number of 
SWDs, C) the mean duration of SWDs. Different colors denote different doses of ETX (black = control; 
purple = 0.3mg; orange = 0.6mg; yellow = 1.2mg; green = 2.0mg; blue = 2.5mg).The left panels show 
the time course of the respective parameter over 12h (one-hour bins) after i.c.v. treatment with 
different doses of ETX (solid lines and symbols indicate the mean, shaded areas indicate ± SEM). The 
bar plots in the middle panels display the average/hour (± SEM) for the distinct parameter, 
considering the best five hours of recording. The right panels show the within animal analysis of the 
percentage of control for the best five hours. The dots represent individual animals. The statistical 
analysis was performed by one-way ANOVA with Tukey’s post-hoc test. (*)P ≤ 0.05, (**) P ≤ 0.01,(***) 
P ≤ 0.001, (****) P ≤ 0.0001. 
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Unilateral i.c.v. application of VPA 
The i.c.v. treatment with VPA, regardless of the dose, did not induce complete seizure 
suppression; however, a dose-dependent antiepileptic effect could be identified.  
Interestingly, the results imply that the relatively low dose of 0.6 mg is the most 
promising local concentration (fig. 3.7A; left panel). The i.c.v. application of 0.6 mg 
induced the greatest drop in cumulative SWD duration. Also, the usage of 2.0 mg VPA 
locally induced suppression of SWD numbers in GAERS. The anticonvulsant effect 
appeared with a time delay of approximately two hours and lasted between two and 
three hours (fig. 3.7A; left panel). The treatment with other VPA concentrations did not 
result in an apparent decrease in seizure occurrence. Interestingly our analysis revealed, 
that on average, the animals injected with 0.3 mg VPA intraventricularly spend more 
time in seizures after treatment than the controls (fig. 3.7A; left panel). Independent of 
treatment, the time courses of epileptic activity followed the expected circadian rhythm 
(cf. fig. 3.3) with an initial period of stability followed by a peak between 2 am, and 4 am 
and a subsequent decline. Taking the entire 12-hour recordings into account, none of the 
doses showed a significant change in seizure activity compared to the control 
experiments (p ≥ 0.78). 
 
To take into account the limited duration of the anticonvulsant activity, we evaluated in 
more detail the therapeutic effect of the different VPA doses for the two consecutive 
hours showing the most robust decrease in epileptic activity. The two-hour time-
window was chosen based on the visual inspection of SWD dynamics over time (fig. 3.7; 
left panels) and on our finding of the pharmacokinetics of VPA after systemic treatment 
(fig. 3.4; green trace). The most effective time window – termed “best two hours” from 
now on – was determined via a sliding window separately for each animal, as we 
observed intraindividual variability. The best two hours started on average 1.8 hours 
after treatment. Note that the i.c.v. injection of 0.3 mg VPA induced an increase of 
epileptic activity in GAERS. Thus, we chose for this dose a defined time window between 
7 pm – 9 pm for the statistical analysis of SWD incidences and mean duration of seizures.  
 
The 0.6 mg VPA was the only dose that statistically significantly affected the cumulative 
duration of SWDs compared to vehicle injection over the best two hours (p=0.024)  
(fig. 3.7A; middle panel). The i.c.v. treatment with 0.6 mg VPA reduces the time in 
seizures by 75.71 ± 4.66 % (mean ± SEM) compared to vehicle injection (fig. 3.7A; right 
panel). The i.c.v. application of 2.0 mg in GAERS reduced the cumulative time of SWDs by 
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about 63.5 ± 8.31 % (mean ± SEM), although this was statistically insignificant based on 
the absolute values. 
 
For the purpose of clarity, only the doses which evoked noticeable changes in epileptic 
activity (0.3 mg, 0.6 mg, 2.0 mg) are shown in the graphs displaying the number of SWDs 
and the mean duration of SWDs in figure 3.7B and C. The treatment with the most 
effective dose of 0.6 mg VPA induced a significant decrease in the number of SWDs  
(p=0.0009) as well as in the mean duration of SWDs (p=0.001) compared to vehicle 
injection. Also, the local treatment with 2.0 mg VPA significantly reduced the number of 
SWDs (p=0.0018); however, the mean duration of SWDs was not significantly affected 
(p=0.07). The application of 0.3 mg VPA significantly promoted the emergence of SWDs 
(p=0.007) without an apparent impact on the mean duration of seizures (fig. 3.7B and C; 
middle panels).  
 
When expressed as percentage of control in a within animal comparison, we found a 
reduction to 40.62 ± 7.93 % (mean ± SEM) in seizure incidences and to 63.97 ± 11.59 % 
(mean ± SEM) in mean SWD duration after treatment with 0.6mg VPA. In conclusion, the 
number of seizures was more effected by locally applied VPA of the most effective dose 
than the mean duration of SWDs (fig. 3.7B and C; right panels). 
 
In summary, this analysis indicates that intra-ventricular injection of low dose of VPA or 
ETX produced a dose-dependent anticonvulsant effect. For VPA, we found the most 
potent anticonvulsant effects with 0.6 mg/animal, whereby increased doses did not 
increase the therapeutic effect. The dose of 0.3 mg VPA appeared to promote epileptic 
activity, indicating that the therapeutic window for intracerebroventricular anti-absence 
therapy with VPA is rather narrow. The local treatment with ETX showed strong 
anticonvulsant effectiveness for doses above 0.6 mg. The therapeutic effects of ETX 
lasted considerably longer than those of VPA. For ETX, we found a U-shaped relation 
between dose and seizure suppression with the strongest anticonvulsant effects at 2 
mg/animal ETX with unilateral i.c.v. injections. We thus focused on this drug and dose 
for subsequent experiments. 
We also found that i.c.v. treatment with the most effective VPA dose had a slightly higher 
effect on the number of SWDs than on the mean duration of SWDs. In contrast, the 
treatment with the most effective ETX dose showed the opposite result. These findings 
may indicate different sites of action after the local application of the two AEDs. 
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Figure 3.7: Epileptic activity in GAERS after i.c.v. treatment with different doses of VPA  
The analysis of epileptic activity is divided into A) the cumulative duration in SWDs, B) the number 
of SWDs, C) the mean duration of SWDs. Different colors denote different doses of VPA (black = 
control; purple = 0.3 mg; orange = 0.6 mg; yellow = 1.2 mg; green = 2.0 mg; blue = 2.5 mg). Left panels 
show the time course of the respective parameter over 12h (one-hour bins) after i.c.v. treatment 
(solid lines and symbols indicate the mean, shaded areas indicate ± SEM). The bar plots in the middle 
panels display the average/hour (± SEM) for each parameter considering the best two hours of 
recording. The right panels show the within animal analysis as percentage of control for the best two 
hours. The dots represent individual animals. The statistical analysis was performed by one-way 
ANOVA with Tukey’s post-hoc test. (**) P ≤ 0.01,(***) P ≤ 0.001, (****) P ≤ 0.0001. 
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3.6 Intracranial versus systemic treatment with ETX  
The previous results did show a strong anticonvulsant effect of i.c.v. treatment with low 
doses of ETX. However, it is uncertain if via the i.c.v. route quantitatively significant drug 
concentrations reach deep parenchymal tissue. It has been suggested that i.c.v. applied 
substances rapidly exchange between CSF and blood. Hence the observed therapeutic 
effects could rather result from a slow intravenous infusion via the CSF than from a direct 
penetration of brain tissue from the CSF (Pardridge, 2016). If this was true, the 
intravenous (i.v.) injection of low doses ETX should result in similar anti-absence efficacy 
compared to i.c.v. treatment. In order to address this question, we treated an additional 
eight animals with the doses of 2 mg/animal ETX sequentially via i.c.v., i.p. or i.v. 
administration routes and directly compared the antiepileptic efficacy. 
 
In compliance with the previous results, the i.c.v. application of ETX induced a strong 
seizure reduction by more than 66.69 ± 3.31 % (mean ± SEM) over the best five hours 
compared to vehicle injection. In strong contrast, administration of 2 mg ETX either via 
i.v. or i.p. injection did not produce any attenuation of SWDs considering percentage of 
control (i.v. = 104.89 ± 9.95 %, i.p. = 94.44 ± 19.40 % (mean ± SEM); fig. 3.8A; right panel). 
Statistical analysis using the average time GAERS spend in seizures after vehicle injection 
(n=24) showed a small but significant decrease in cumulative seizure duration for the 
i.v. treatment with 2.0 mg ETX (p=0.035) but not for the i.p. injection (p=0.18) 
(fig. 3.8A; middle panel). The comparison between different administration routes 
confirmed a significantly better anticonvulsant effect over the best five hours for i.c.v. 
application of ETX versus i.p. or i.v. application (i.c.v. vs. i.v.: p=0.0244; i.c.v. vs. i.p.: 
p=0.0046, fig. 3.8A; middle panel).  
Furthermore, if seizure suppression was quantified for the entire recording time of 12 
hours, we found that i.p. or i.v. administration had no significant effect on SWD, but i.c.v. 
administration caused a significant reduction in seizure duration (data not shown,  
p=0.007). These results indicated that the therapeutic efficacy of ETX strongly depended 
on the administration route and revealed that i.c.v. application is by far more efficient 
than systemic routes of drug application in low doses.  
 
Finally, we directly compared the efficiency and dynamics of seizure suppression after 
ETX treatment by either i.c.v. application of 2 mg/animal ETX (all tested animals n=20) 
or systemic treatment with 100 mg/kg ETX (n=7) (fig. 3.8 B). 
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Whereas seizure suppression started immediately after i.p injection, it was delayed 
approximately 2 hours after i.c.v. injection. Besides, the duration of the anticonvulsive 
effect was extended after i.p. high-dose application compared to i.c.v. low-dose 
application. The cumulative time in SWDs was decreased by approximately 85% after 
i.p. and by 58% after i.c.v. injection for the best 5 hours, which suggested that high-dose 
i.p. application is about 25% more efficient than low-dose i.c.v. application (fig. 3.8B; 
right panel). In summary, these data indicated that unilateral i.c.v. application of low 
doses of ETX showed a delay in onset, shorter duration, and slightly lower amplitudes of 
therapeutic efficacy when compared to standard high dose systemic therapy. 
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Figure 3.8: Epileptic activity in GAERS after ETX treatment using different application 
routes  
The right panels show the time course of the cumulative duration in SWDs over 12h (one-hour 
bins) after treatment (solid lines and symbols indicate the mean, shaded areas indicate ± SEM). 
The bar plot in the middle represents the average ± SEM time GAERS spend in seizures within one 
hour, considering the most effective five hours after drug administration. The right panels show 
the within animal analysis of the percentage of control for the most effective 5 hours. The dots 
represent individual animals. Different colors denote different application methods (black = 
control; blue = i.p. (2 mg/animal); yellow = i.v. (2 mg/animal); green = i.c.v. (2 mg/animal); pink 
= i.p. (100 mg/kg)). A) Compares i.c.v. application with systemic treatment (i.v. or i.p.) utilizing 
the same drug dose (2 mg/animal; n=8). B) Compares i.c.v. application of 2 mg/animal ETX 
(n=20) with the standard therapeutic dose (100mg/kg) of intraperitoneal applied ETX (n=7). The 
statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test. (*)P ≤ 0.05, (**) 
P ≤ 0.01,(***) P ≤ 0.001, (****) P ≤ 0.0001. 
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3.7 ETX distribution throughout different body compartments after 
i.c.v. and systemic administration 
The intracranial application of ETX significantly reduced the occurrence of SWDs in 
GAERS at a dose of 2.0 mg/animal, as shown in the previous results (fig. 3.6). 
Furthermore, we could show that at these low doses, the i.c.v. application of ETX is more 
efficient compared with systemic drug application (fig. 3.8). Increased intracranial drug 
concentrations, after localized drug injection, could explain these results. 
 
In order to compare how the application routes – i.c.v. or i.v. – affect ETX distribution in 
the brain, the drug concentrations were analyzed in blood plasma, CSF, and brain tissue 
after the respective treatment. For systemic ETX application, it has been reported that 
the AED rapidly and evenly distributes (distribution volume of 0.7 l/kg) throughout the 
body, including brain tissue and CSF (Gören and Onat, 2007). We were particularly 
interested in the ETX concentration within brain areas involved in absence epilepsy, i.e. 
thalamus and somatosensory cortex (Meeren et al., 2005). To further investigate 
whether the distinct time course of seizure suppression (fig. 3.6A; left panel) is related 
to the distribution properties of ETX, samples were taken at three different time points 
after drug injection (15 min, 1 hour, and 4 hours). Finally, we analyzed if drug 
concentrations differed between brain hemispheres, as ETX was applied unilaterally.  
  
Figure 3.9: ETX distribution in CSF and plasma after i.v. or i.c.v. treatment  
The ETX concentration (μg/ml) in CSF and plasma after i.c.v. (2mg/animal; dark grey) or i.v. 
(2mg/animal; light grey) drug administration at different time points (mean ± SEM). The statistical 
analysis was performed by one-way ANOVA with Tukey’s post-hoc test. (*)P ≤ 0.05. 
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Figure 3.10: ETX distribution in brain parenchyma after i.v. or i.c.v. treatment 
ETX concentration (μg/g) in the cortex and thalamus (Th) after i.c.v. (2mg/animal; dark 
grey), or i.v. (2mg/animal; light grey) drug administration at different timepoints (mean 
± SEM). The (+) denotes the hemisphere with canula implantation and the (–) without 
cannula implantation. The middle panel shows a schematic representation of a coronal 
section, which highlights the dissected areas and the injection site. The statistical analysis 
was performed by one-way ANOVA with Tukey’s post-hoc test. 
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A slight but steady decrease of the ETX concentration, independent of the application 
method, can be observed in the CSF and plasma over time (fig. 3.9). Although the 
concentration change over time was not statistically significant but in line with the 
proposed half-life of ETX in rats (Löscher, 2007). The ETX was already after 15 minutes, 
evenly distributed throughout the CSF and plasma, and the measured drug 
concentrations were hardly affected by the application method. Only the i.c.v. application 
of ETX resulted, after 15 minutes, in significantly higher drug concentration in the CSF 
compared to the corresponding i.v. injections (fig. 3.9; left panel). Though it is important 
to note that CSF samples contaminated with blood were excluded from the analysis, and 
we thus only included two out of four samples collected 15 minutes after i.c.v. treatment 
in the analysis. In all other tests the four samples could be used. The samples from the 
control experiments (vehicle injections) showed no traces of ETX in plasma or CSF (cf. 
supplementary data; tab. S.2). 
The analysis of drug distribution in the brain tissue showed 15 minutes after treatment, 
higher ETX concentrations in the thalamic compared to cortical areas (i.c.v. and i.v.) in 
both hemispheres, although this was statistically insignificant (fig. 3.10). One hour after 
drug application, ETX was evenly distributed throughout the brain areas. Interestingly, 
i.c.v. application of ETX did not result in higher local drug concentration compared to 
intravenous drug injections. However, the samples collected after vehicle injection 
(control samples) also showed ETX concentration in the thalamus and cortex 
(cf. supplementary data; tab. S.2). Therefore, a careful interpretation of the measured 
ETX concentration in the brain tissue is necessary.   
Figure 3.11: ETX distribution throughout different body compartments 
after standard systemic high dose treatment 
A) ETX concentration (μg/ml) in CSF and plasma one hour after i.p. (100 
mg/kg) drug administration. B) ETX concentration (μg/g) in the cortex and 
thalamus one hour after i.p. (100 mg/kg) drug administration (mean ± SEM). 
The statistical analysis was performed by one-way ANOVA with Tukey’s 
post-hoc test. 
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Samples after standard systemic high dose treatment with 100 mg/kg ETX (i.p.) were 
taken one hour after treatment. The CSF and plasma reached ETX-levels approximately 
18-fold higher compared to i.c.v. treatment with 2 mg ETX (fig 3.11 and fig. 3.9). 
Furthermore, in the thalamus and cortex, considerably higher AED concentrations could 
be found. These results show that ETX rapidly distributes between compartments 
independent of the application route, which is in accordance with its linear distribution 
kinetics (Patsalos, 2005). However, because of the deficient control experiment, the final 
interpretation of ETX levels in brain parenchyma is impossible (cf. Chapter 4.5).   
 
3.8 Substance entry into brain parenchyma after i.c.v. injection 
To approach the question why i.c.v. treatment was so much more effective in seizure 
suppression than systemic treatment with the same dose of ETX despite similar 
concentrations in plasma and CSF we made i.c.v. dye injections with fast green (FG) to 
visualize substance penetration into brain tissue after unilateral i.c.v. injection (fig. 3.12). 
Directly after FG administration, the substance appears well distributed throughout the 
ventricular system with little transfer into the brain parenchyma (fig. 3.12A). However, 
one hour after dye administration, FG clearly stained the tissue surrounding the 
ventricles, including the potential target sites of ETX in absence epilepsy, such as 
thalamic areas around the third ventricle and somatosensory cortical areas (fig. 3.12B). 
At four hours post FG injection, we found extensive staining of relevant areas also at 
larger distance to the ventricular system (fig. 3.12C). 
Interestingly, obvious staining one and four hours after dye injection remained largely 
restricted to the ipsilateral side of injection. Accordingly, although FG differs from ETX 
in molecular size and polarity, which in turn will influence tissue distribution, these data 
could indicate that ETX after i.c.v. injection reaches its target areas by direct penetration 
into brain tissue from the CSF rather than indirect recirculation via the blood. 
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Figure 3.12: Dye tissue distribution after i.c.v. fast green administration  
Ventricles and structures, which are known to be involved in the generation of 
absence seizures are labeled.  NRT, reticular thalamic nucleus; VB, ventrobasal 
thalamus; S1, primary somatosensory cortex; LV, lateral ventricle; 3V, third 
ventricle. Images show dye distribution A) five minutes B) one hour and C) four 
hours after dye injection.     
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3.9 Adverse effects after i.c.v. application of ETX 
To evaluate whether localized drug application could indeed be an alternative and 
effective treatment approach in absence epilepsy, we had to also test for neurotoxic 
effects after intracerebroventricular ETX administration. All intracranial applied ETX 
concentrations (0.3 mg, 0.6 mg, 1.2 mg, 2.0 mg, 2.5 mg) were tested each in five animals.  
The Open Field-Test (OF) was used to detect behavioral abnormalities and locomotor 
deficits in the animals (Honack and Löscher, 1995). Sedation and ataxia, as well as 
stereotyped behaviors including circling, head swinging, or stereotypical sniffing in the 
OF, are possible indicators for adverse effects of localized drug application. However, the 
animals tested in the OF, after i.c.v. treatment with ETX scored zero for all parameters 
regardless of drug concentration. 
To further determine if i.c.v. treatment affects the rat's responses to external stimuli, a 
hyperexcitability test (HET) was performed with the animals. During the HET, the 
experimenter was interacting with the rats and scoring their behavior  
(cf. Chapter 2.7; tab 4). Indeed, the scores of the ETX injected animals did not differ from 
the vehicle controls (fig. 3.13B). 
Motor coordination of i.c.v. treated animals was assessed by the rotarod test 
(Dunham and Miya, 1957). Thus, the animals had to balance on a rod that rotated at a 
specific speed (cf. Chapter 2.7). To pass this test, the rats had to stay on the rod without 
falling off for at least 2 min in one of three trials. All tested animals passed the rotarod 
test before and after i.c.v. treatment with ETX, regardless of concentration. 
A significant reduction in body weight of the GAERS could only be observed after 
treatment with the highest concentration of 2.5 mg compared to vehicle injection 
(p=0.02) and to no treatment (p=0.04) (fig. 3.13A).  
The behavioral results indicated that i.c.v. treatment does not cause adverse effects in 
GAERS, especially 2.0 mg ETX, the most promising dose, was well tolerated by all 
animals. 
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Figure 3.13: Adverse effects in response to unilateral i.c.v. administration of ETX 
All behavioral tests were performed with non-treated animals (baseline), vehicle-injected animals (saline), and 
ETX injected animals (ETX). For ETX treatment, different doses were tested. The colors of the dots and error 
bars denote the used doses of ETX (green = 0.3 mg; turquoise = 0.6 mg; blue = 1.2 mg; dark purple = 2.0 mg; 
purple = 2.5 mg). A) Shows the body weight of the animals after the different treatments (mean ± SEM). B) The 
HET consist of four subsequent behavioral tests: the approach-response test, the touch-response test, the 
finger-snap test, and the pick-up test. The dots present the mean ± SEM score given by the experimenter. The 
statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test. (*)P ≤ 0.05. 
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3.10 Unilateral cortical ETX application via an Epidural cup 
The “cortical focus theory” implies that absence seizures are initiated in the 
somatosensory (S1) cortex of rodents (Meeren et al., 2005) and pharmacological studies 
showed, that the injection of ETX into the S1 cortex of GAERS immediately and nearly 
complete suppresses SWDs (Manning et al., 2004). Therefore, we investigated an 
alternative application route for AEDs in closer proximity to the S1 cortex. To this end, 
we removed parts of the skull and installed an epidural cup directly on the cortical 
surface (cf. Chapter 2.2; fig. 2.2). The dura mater was left intact during the procedure, as 
it has been shown that transmeningeal substance delivery is possible (Ludvig et al., 
2008). The surgery was little invasive, and the cortical surface provided enough space 
for a potential drug depot. The epidural application method was tested in three animals 
with two different concentrations of ETX (1 mg and 2 mg). However, for both 
concentrations, no therapeutic effect in GAERS could be observed at any time point 
(fig. 3.14).  
 
Figure 3.14: Epileptic activity in GAERS after epidural ETX application  
The left panel shows the time course of the cumulative duration of SWDs over 12h 
(one-hour bins) after epidural ETX application with the doses 1.0 mg (pink) and 2.0 
mg/animal (purple; n=3). The reference (black; n=3) displays epileptic activity after 
vehicle application (solid lines and symbols indicate the mean, shaded areas indicate ± 
SEM). The bar plot represents the average±SEM time GAERS spend in seizures per 
hour, considering the complete time of recording. Statistical analysis reveals no 
significant difference between the vehicle and drug application. The statistical analysis 
was performed by one-way ANOVA with Tukey’s post-hoc test. 
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3.11 Unilateral i.c.v. application of the neuropeptides Neuropeptide 
Y and Somatostatin 
Neuropeptides are key modulators of neural activity and have been discussed as 
potential alternatives to classic antiepileptic drugs for several years (for a review see 
Kovac and Walker, 2013). In particular, neuropeptides are potent even at low doses. 
However, they show poor blood-brain barrier penetration, which hinders their systemic 
application but makes them attractive candidates for localized pharmacotherapy in 
epilepsy. 
One of the best-explored neuropeptides in the context of epilepsy is the Neuropeptide Y 
(NPY). It has already been shown that NPY, when injected intracerebroventricularly, 
effectively suppresses SWDs in GAERS over 90 minutes at a dose of 6 nmol (Stroud et al., 
2005). In order to verify in more detail, the therapeutic potential of NPY, we included 
this neuropeptide in our study. Furthermore, the efficacy of another neuropeptide, 
Somatostatin (SST), for localized therapy in absence epilepsy was tested. We chose SST 
because, in status epilepticus, this neuropeptide showed similar anticonvulsant efficacy 
as NPY at a dose of 1nmol (Mazarati and Wasterlain, 2002). However, SST has to our 
knowledge not yet been tested in a model for absence epilepsy.  
 
The i.c.v. injection of NPY did not produce any attenuation of SWDs over the complete 12 
hours neither for 10 nmol (p=0.7) or for 100 nmol (p=0.9) compared to vehicle injection 
(fig. 3.15A; left panel). To directly compare our results to those reported in the literature, 
we analyzed in more detail the first 90 minutes after treatment (Morris et al., 2007; 
Stroud et al., 2005) (fig. 3.15B; left panel). Therefore, the percentage of time spent in 
seizures was plotted in 15-minute time bins. However, even the higher time resolution 
did not reveal any clear anticonvulsant effects of NPY.  
Also, the i.c.v. application of 2 nmol (p=0.9) or 20 nmol (p=0.1) of the neuropeptide SST 
did not influence seizure activity in GAERS over the complete 12 hours (fig. 3.15A; right 
panel). Three hours after i.c.v. treatment with 20nmol SST, an increase in cumulative 
seizure duration of SWDs can be observed. However, this increase was not statistically 
significant (p=0.45) compared to controls at this time point. Furthermore, the closer 
evaluation of the first 90 minutes after treatment did not reveal any antiepileptic activity 
of SST (fig. 3.15A; right panel). In summary, the i.c.v. application in GAERS of the 
neuropeptides NPY or SST did not show any anti-absence effects in our hands. This 
approach for localized drug therapy was thus not further pursued in this study. 
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Figure 3.15: Epileptic activity in GAERS after i.c.v. treatment with different doses of NPY and 
SST 
A) The left panel shows the time course of the cumulative duration of SWDs over 12h in one-hour 
bins after i.c.v. treatment with the NPY doses 10 nmol (blue; n=7) and 100 nmol/animal (green; n=7). 
The right panel shows time in seizures over 12h after i.c.v. treatment with the SST doses 2nmol (red; 
n=7) and 20nmol/animal (yellow; n=7). Black traces in both panels show the time spent in epileptic 
activity after vehicle injection (n=14) (solid lines and symbols indicate the mean, shaded areas 
indicate ± SEM). B) The left penal shows the time course of percentage time in SWDs over 90 minutes 
in 15 minutes bins after i.c.v. treatment with the NPY doses 10 nmol () and 100 nmol/animal (). 
The right panel shows the time course of percentage time in SWDs over 90 minutes in 15 minutes 
bins after i.c.v. treatment with the SST doses 2nmol () and 20nmol/animal (). Statistical analysis 
revealed no significant differences between the vehicle and neuropeptide application. The statistical 
analysis was performed by one-way and two-way ANOVA with Tukey’s post-hoc test. 
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3.12 Brain activity and SWDs during chloral hydrate anesthesia  
It is imperative to quantify seizure occurrence directly after drug application while 
testing antiepileptic efficacy of a substance, in order to understand the time course of the 
pharmacological effect. Thus, the implantation of a drug-releasing material requires that 
the animals are under anesthesia. Therefore, we were interested in evaluating if seizures 
arise under chloral hydrate anesthesia (400 mg/kg) and/or how long after anesthesia 
seizure detection becomes possible again. Typically, general anesthesia evokes a 
characteristic EEG pattern, so-called burst suppression (Swank and Watson, 1949; 
Urrego et al., 2014). The background EEG during anesthesia, which is referred to as 
“suppression period,” is dominated by flat amplitudes with a dominating frequency 
between 0.5-4.0 Hz. The EEG trace is consistently interrupted by quasiperiodic, high 
amplitude “bursts”. Undergoing chloral hydrate anesthesia, all three recorded animals 
showed these characteristic burst suppression patterns starting approximately 10 
minutes after chloral hydrate application. In figure 3.16A, typical burst suppression 
patterns in a 60 second EEG recording of one animal under chloral hydrate anesthesia 
are shown. During the bursts, the spectrogram shows a high power in all frequency 
ranges up to approximately 40 Hz (fig. 3.16B). The start and termination of the bursts 
were abrupt, and the amplitudes varied between 0.1 – 0.3 mV. Compared to SWDs, the 
bursts were brief and did not show a characteristic oscillatory morphology 
(fig. 3.16A & fig. 3.1A). Therefore, false positive “ictal” classification by automated 
detection did not appear. 
The anesthetic period, showing burst suppression patterns, lasted approximately 40 
minutes. Afterward, the animal’s EEG recordings displayed brain activity typical for 
deep-slow wave sleep (Bjorvatn et al., 1998). Hence the neural oscillations were 
dominated by delta waves, i.e. high amplitudes and frequencies between 1 – 5 Hz (data 
not shown). Five hours after chloral hydrate injection, the first seizures could be 
recognized by automated detection (fig. 3.16A). The cumulative time in seizures reached 
baseline values six hours after the injection of the anesthetic. As a reference, the average 
time GAERS spend in seizures from the baseline sessions of all recorded animals (n=61) 
was included in the graph shown in figure 3.16A.  
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Figure 3.16: Chloral hydrate anesthesia affects brain activity and SWDs 
A) The 60 second EEG recording shows typical burst suppression in a GAERS rat under chloral hydrate 
anesthesia. The enlarged EEG complex displays a characteristic burst with high amplitudes. B) The 
power spectrogram corresponding to the EEG recording reveals low frequencies during the suppression 
phase and during the bursts, high power in all frequencies up to 40 Hz. C) The blue trace in the time 
graph (one-hour bins) shows the cumulative duration GAERS spent in seizures over 12h after chloral 
hydrate injection (n=3). The black trace is included as a reference and contains the average seizure 
duration over 12h from the baseline sessions (n=61) (solid lines and symbols indicate the mean, shaded 
areas indicate ± SEM). The first five hours after the anesthetic injection, no seizures could be detected; 
however, after six hours the animals under chloralhydrate anesthesia showed similar epileptic activity 
as the baseline group. 
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4 Discussion  
Absence epilepsy is one of the most common types of childhood epilepsy and is 
characterized by sudden and recurring non-convulsive seizures accompanied by the loss 
of consciousness and behavioral arrest. The seizures result from aberrant neural activity, 
which can be observed as characteristic patterns in the electroencephalogram (EEG) 
dominated by spike-and-wave discharge (SWD) (Crunelli and Leresche, 2002). The 
thalamocortical networks appear to play a critical role in the emergence and 
maintenance of SWDs (Lüttjohann and van Luijtelaar, 2015; Steriade, 1990) and the 
respective brain areas are suggested to be the targets of pharmacological treatment 
(Manning et al., 2003).  
The systemic application of antiepileptic drugs (AEDs) is the current mainstay to treat 
epilepsy. Although the drug transport into the CNS via the blood is highly restricted by 
the blood-brain barrier (BBB) and thus high drug concentrations in the systemic 
circulation are required to suppress seizures (cf. Chapter 1.6). The direct drug 
application into the thecal sac, that surrounds the CNS and contains cerebrospinal fluid 
(CSF), may be a potential alternative approach to treat epilepsy. Intrathecal (IT) drug 
application would minimize side effects caused by off-target drug exposure in the 
periphery and increase neuroactive components in the CNS (Fowler et al., 2020). This 
study aimed to test if IT treatment can robustly control seizures in the genetic absence 
model GAERS and to compare the anticonvulsant efficiency of different application 
approaches. 
4.1 Automated detection of spike and wave discharge in GAERS  
The quantification of epileptic activity and seizure suppression is a particularly precise 
tool in the assessment of the efficacy of antiepileptic therapy. The SWDs, of GAERS, show 
characteristic and repeating patterns in the EEG (fig. 3.1). On this basis we were able to 
successfully implement automated seizure detection algorithms using the computed 
autocovariance of one-second data segments as feature vectors (Rodgers et al., 2015). 
With this method, seizure detection achieved an F-score of 96 % (fig. 3.2), which is 
comparable to other seizure detection applications (van Luijtelaar et al., 2016).  
Detection errors of our classifier often appeared at the end or the beginning of a seizure, 
more precisely, within those time windows, in which the switch between brain states 
(ictal  interictal) occurred (fig. 3.2A). It is possible that an increase in the time 
resolution of seizure detection would reduce this type of error. Hence, the application of 
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a sliding window with a smaller step-size instead of computing the autocovariance for a 
fixed time window of one second would be favorable.  
Further possible detection errors occur because of local field potential (LFP) 
components, that resemble SWDs (e.g. sleep spindles and artifacts caused by head 
movements or grooming). During preprocessing of the data movement artifacts have 
been reduced by high pass filtering the data at 5 Hz, and most sleep spindles were 
correctly classified as non-ictal by seizure detection, as we set the condition that SWDs 
had to last longer than one second. Nevertheless, a more advanced processing procedure 
of the recorded data could be advantageous to increase seizure detection specificity. 
Whereas seizure detection performance was adequate for the aims of this study, future 
applications such as e.g. a “closed-loop” device that converts online seizure detection 
into immediate, controlled drug release would benefit from enhanced detection 
performance. 
4.2 The dynamics of spike and wave discharge  
The 24-hour and 12-hour recordings of untreated GAERS revealed endogenous 
undulations of seizure activity with a peak accumulated time in SWDs between 2 am and 
4 am (fig. 3.3). This observation agrees with earlier studies, that showed that epileptic 
activity depends on the vigilance level in this model organism. SWDs increase during 
passive wakefulness and light stages of non-rapid eye movement sleep (NREM), but 
occur more sporadically during active arousal, slow-wave and paradoxical sleep 
(Drinkenburg et al., 1991; Van Luijtelaar and Coenen, 1988). This tendency of SWD 
occurrence is shared between humans and rats (Kellaway et al., 1980). These findings 
indicated that epileptic activity in parts temporally coincidences with the occurrence of 
the majority of sleep spindles (Dijk et al., 1993), which supported the hypothesis that 
sleep spindles and SWDs may result from identical thalamocortical interactions and that 
sleep-related circuits get co-opted to generate epileptiform activity (Beenhakker and 
Huguenard, 2009).  
However, sleep spindles are generated in the intra-thalamic circuit, whereas cortico-
thalamic inputs seem to be required to initiate SWDs (Meeren et al., 2002). Thus, in 
recent years it has been critically discussed, whether SWDs indeed result from aberrant 
oscillations of natural sleep (Leresche et al., 2012). 
Nonetheless, consensus exists that the neuronal networks in the thalamocortical loop 
play distinct functional roles in the generation, maintenance and seizure termination. 
The cortical focus theory assumes that SWDs are initiated in the S1 cortex  
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(Meeren et al., 2005). The thalamus has been proposed to tilt the system towards a pro 
epileptic state and to function as a resonator in SWD maintenance. Finally, the 
termination of seizure activity is probably initiated by cortico-thalamic as well as intra-
thalamic processes (Lüttjohann and van Luijtelaar, 2015). Based on these dynamics it 
can be concluded that the mechanisms involved in initiation, maintenance and 
termination are reflected in some of the SWD features: the number of SWDs per time is 
mainly determined by the excitability of the cortex, whereas the mean duration depends 
on mechanisms involved in aborting ongoing SWDs in the thalamus (Lüttjohann et al., 
2014). On average the untreated animals spent about 300s/h in seizures. The total time 
in seizures is composed of approximately 30 seizures per hour with a mean duration of 
10 seconds (fig. 3.3).  
4.3 Suppression of SWDs by systemic application of the therapeutic 
doses of VPA or ETX 
Systemic drug delivery is the conventional method to treat disorders of the CNS, 
although the BBB prevents the movement of active agents between the peripheral 
system and the CNS to a significant degree. Only a minute fraction of small molecules and 
hardly any large-molecules can access the brain (Pardridge, 2005). However, it is a major 
advantage of systemic drug application that every neuron is in close proximity to a brain 
capillary (Schlageter et al., 1999). Therefore, diffusion distances to the site of action are 
very short for substances that cross the BBB after systemic application. To assess IT drug 
application as an alternative to systemic application we set out to compare these two 
routes regarding therapeutic efficacy and dynamics. Accordingly, we initially evaluated 
the anti-epileptic activity of systemically applied VPA and ETX as reported in the 
literature to generate reference values to assess subsequent IT drug application 
efficiency. 
The high predictive validity of GAERS, make them an excellent model to evaluate the anti-
absence action of novel pharmaceutical strategies (van Luijtelaar and van Oijen, 2020). 
The predictive validity refers to assessing medication effects in humans based on the 
animal models response to drug application. The most commonly used drugs in 
childhood absence epilepsy are ethosuximide (ETX), and sodium valproate 
(VPA)(Manning et al., 2003). The effectiveness of these AEDs has also been 
demonstrated at a therapeutic concentration in GAERS (Marescaux et al., 1992).  
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In accordance with previous findings, the administration of a standard systemic 100 
mg/kg ETX dose produced an immediate and strong suppression of SWDs over 
approximately 11 hours. Seizure suppression was nearly complete over the first five 
hours, after which the epileptic activity gradually increased again (fig. 3.4; pink trace). 
Interestingly, in the first few hours after ETX treatment the number and duration of 
SWDs were both affected, which has also been described by van Luijtelaar et al., 2013. 
Approximately five hours after drug application seizure duration recovered and the 
decreased number of SWD incidences was sufficient to explain the anti-absence effect of 
ETX. A possible explanation is that the drug-induced anti-absence mechanisms initially 
affect both cortex and thalamus but that these actions persist longer within cortical brain 
areas. However, these observations could also be compromised by analytical problems, 
as too few seizures have been recorded in the first five hours (approximately 1 or 2 
seizures per hours). Consequently, the seizure duration would hardly be affected by the 
systemic treatment of ETX, which could indicate that the anti-absence effect over the 
entire therapeutic time window is mainly caused by drug effects in the cortex (Greenhill 
et al., 2012; van Luijtelaar and van Oijen, 2020). 
 
The anticonvulsant action of systemic VPA was also instantaneous, but considerably 
shorter compared to ETX. The anti-absence efficacy was apparent only over the first two 
hours after i.p. injection of the therapeutic dose of 200 mg/kg VPA. The short duration 
of seizure suppression for VPA could be explained by active, carrier-mediated transport 
at the BBB (Frey and Löscher, 1978), which supports the fast entrance of VPA into the 
CNS but also results in rapid extrusion from the brain. Moreover, the half-life of VPA  
(2 – 3 hours) is considerably shorter compared to ETX (10 – 16 hours) (Löscher, 2007). 
Within the therapeutic time window of approximately two hours both seizure duration 
and SWD incidence were significantly decreased.  
  
Discussion  Chapter 4 
 85 
4.4 Exploration of alternative application routes – 
intracerebroventricular application of VPA and ETX  
Our approach to bypass the BBB in order to increase the drug concentrations 
intracranially was the IT administration of substances. Drug application into the CSF was 
achieved by injection into the right lateral ventricle (intracerebroventricular - i.c.v.). We 
examined, whether i.c.v. drug delivery could principally be an option for the treatment 
of epileptic disorders. To this end, we have systematically investigated the therapeutic 
effects of i.c.v. injections of ETX and VPA. 
 
The unilateral i.c.v. application of ETX and VPA showed a dose-dependent reduction of 
epileptic activity (fig. 3.6 & fig. 3.7). For ETX, similar results were reported earlier for 
WAG/Rij rats, which represent another established absence epilepsy model (van 
Luijtelaar et al., 2000). This study reported sufficient SWDs suppression by injecting  
0.3 mg ETX. In GAERS, however, higher drug doses seem to be required as a significant 
decrease of SWD activity could only be seen for doses higher than 0.6 mg.  
Interestingly, the dose dependence of seizure suppression followed an inverted U shape 
for ETX, and SWD activity started to increase again with drug doses exceeding 2.0 mg  
(fig. 3.6). Similar observations have been made previously with injections of ETX into the 
thalamus (Richards et al., 2003). Our results suggest a therapeutic range between  
1.2 – 2.0 mg for i.c.v. applied ETX. In contrast, administration of the low dose  
(2 mg/animal) did not produce any anticonvulsive effects when applied systemically  
(fig. 3.8). This strongly speaks against the idea that i.c.v. application simply represents a 
slow intravenous infusion (Pardridge, 2016) and instead suggests that ETX penetrates 
into relevant brain regions directly from the CSF (cf. fig. 3.8). 
 
To our knowledge, the i.c.v. application of VPA has not been tested in absence epilepsy 
yet. However, the method was used in a model for temporal lobe epilepsy (amygdala 
kindling epilepsy model). This study showed that high concentrations, approximately  
4.5 mg/animal, generated a significant antiepileptic effect, but were accompanied by 
remarkable ataxia and sedation (Serralta et al., 2006). In GAERS we found a significant 
reduction of SWDs after the i.c.v. application of only 0.6 mg VPA, whereas higher 
concentration did not result in a significant anti-absence effect. Indeed, the application 
of 0.3 mg appeared to exacerbate seizure incidences.  
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VPA has been shown to have biphasic effects on extracellular GABA levels (Biggs et al., 
1992). The i.p. injection of 50 mg/kg VPA decreased GABA levels in the brain of rats 
compared to basal, whereas the injection of 400 mg/kg VPA drastically increased the 
GABA levels. Interestingly, treatment with 200 mg/kg VPA had virtually no effect on 
GABA levels. This may explain the pro-epileptic effects seen at low doses VPA because of 
increased excitability in the cortex. However, high concentrations of VPA may facilitate 
burst firing in the thalamus and thus triggers again SWDs (cf. Chapter 1.2), which may 
occlude the anti-absence effect of i.c.v. applied VPA above a specific dose.  
Furthermore, it has been suggested that the action of VPA in the brain is region specific 
(F. Baldino and Geller, 1981). As i.c.v. treatment will likely achieve variable drug 
concentrations throughout the brain, the contributions of different drug effects in 
different relevant brain regions are hard to predict and likely occlude the interpretation 
of our data on the therapeutic effects of IT applied VPA. In any case, our results indicate 
a rather narrow therapeutic window for i.c.v. application of VPA. I.c.v. treatment with 
concentrations between 0.3 – 2.5 mg did not appear to have an adverse effect in the 
animal. This, however, has to be studied in more detail. 
 
Interestingly, we observed a delayed onset of the therapeutic effects of approximately 
two hours after i.c.v. treatment for both AEDs. A considerable fraction of the therapeutics 
must most likely distribute through the brain's extracellular space to reach its target 
area. The distribution properties of any substance are affected by several factors, 
including the brain microenvironment, tortuous extracellular space, and the substance's 
physiochemical properties (Wolak and Thorne, 2013). Hence, i.c.v. application could 
result in a gradual drug distribution in the CNS and decelerated accumulation of the 
therapeutic agent in the brain's target areas within some distance from the lateral 
ventricle (e.g., thalamus, S1 cortex). The belated reach of therapeutic concentration in 
distinct brain areas could explain the delayed antiepileptic efficacy by i.c.v. applied AEDs 
(cf. fig. 3.12).  
Richards et al. (2003), reported a similar delay in the therapeutic onset after the local 
injection of ETX into the thalamic VB and NRT. The authors have also attributed this 
effect to the distribution dynamics of ETX in brain tissue. An alternative hypothesis 
would be that delayed antiepileptic efficiency is caused by specific, possibly slow, 
mechanisms that are targeted by ETX in the thalamic brain areas. This idea would also 
be in line with the observation that i.c.v. application of ETX, between 2.0 – 2.5 mg, shows 
in contrast to systemic drug administration a more robust effect on seizure duration than 
on the number of seizures. These observations suggest that the therapeutic effects of 
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i.c.v. applied ETX may to a large degree be mediated by effects on thalamic rather than 
cortical structures. Such a bias regarding the site of pharmacological action could also 
explain why the antiepileptic efficiency does not reach a maximum of 100% seizure 
suppression as effects in the cortex are strongly contributing to the anti-absence effect 
of ETX after systemic application (Greenhill et al., 2012).  
The delayed seizure suppression of i.c.v. applied ETX though was not described by the 
above mentioned study of van Luijtelaar et al., 2000. However, by not displaying the 
time-dependent variations of antiepileptic efficacy within their six-hours recordings, 
this effect may have been occluded. 
 
A closer inspection of the time-window of drug action could reveal further insight into 
the pharmacodynamics of IT applied VPA. The systemic application of the therapeutic 
dose of VPA revealed an antiepileptic action of approximately two hours with an 
immediate onset in GAERS, which corresponds with the results from other studies 
(Dedeurwaerdere et al., 2011; Löscher, 2002). The short efficiency could be explained by 
the short half-life of the drug and by transport mechanisms that support the rapid 
removal of the AED from the brain (Frey and Löscher, 1978). Indeed, the i.c.v. application 
of VPA shows a delayed drug efficiency, however, the duration of action persists 
approximately until four hours after application (fig. 3.7). A possible explanation could 
be that the IT applied drugs are not so much affected by efflux mechanisms, though Frey 
and Löscher (1978) showed that the underlying transporters could also be found in the 
CSF-blood barrier. A further interesting aspect could be that the direct application of VPA 
into the CSF is to a lower extent affected by metabolism relative to systemic application, 
leading to a longer half-life of the AED (Misra et al., 2003). Such an increased drug half-
life within the CSF could be a further advantage of IT drug application.  
 
In conclusion, the systemic investigation on whether an IT drug application could be an 
alternative option for the treatment of epileptic disorders, revealed that the i.c.v. 
administration of ETX or VPA caused robust and dose-dependent reductions in SWDs. 
However, complete seizure suppression could not be achieved. Because ETX showed a 
prolonged and more solid anti-absence effect in GAERS compared to VPA, we suggested 
that ETX is a better choice for IT drug applications. Indeed, the effect of locally applied 
ETX was dramatically stronger than the effect after systemic application of the same 
drug dose, which proved that the therapeutic effect was not caused by the indirect entry 
of ETX into brain parenchyma via the bloodstream but rather mediated by a direct entry 
from the CSF. Finally, the animals showed no behavioral or motor deficits after the i.c.v. 
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treatment, suggesting that this application route may indeed be a feasible alternative to 
systemic drug application. 
4.5 Tissue distribution of ETX after treatment via different 
application routes 
The CSF fills the cerebral ventricles, cisterns, as well as the cranial and spinal 
subarachnoid spaces and moves within these compartments (Linninger et al., 2016). 
Accordingly, the CSF is engaging to a great extent with the CNS and has already been 
clinically used as a vehicle for drug transportation throughout the entire brain (Cook et 
al., 2009; Miller et al., 2013). The CSF flow dynamics, which are highly complex and not 
fully understood, are suggested to facilitate the drug penetration into brain tissue after 
IT application (João Casaca-Carreira et al., 2017; Fowler et al., 2020). To understand the 
mechanisms behind the therapeutic action of IT applied ETX and potentially overcome 
limitations of the method, we were interested in monitoring the fate of ETX after 
treatment using different application routes. To this end we utilized HPLC analysis and 
measured ETX concentration within blood plasma, CSF, and brain tissue (i.e. thalamus 
and S1 cortex) at different time points after treatment.  
 
Our results show a fast exchange of ETX between CSF and bloodstream after treatment, 
independent of the dose, timepoint, and application method (cf. fig. 3.9). It was 
surprising that the i.c.v. application of ETX did not show clearly higher drug 
concentrations in the CSF compared to systemic treatment at any timepoint. Thus, an 
immediate blood-CSF exchange of ETX must appear after i.c.v. application. 
However, as discussed earlier, the therapeutic effects of i.c.v. applied ETX is probably not 
caused by the indirect entry of ETX into the brain parenchyma via the bloodstream, but 
rather mediated by the direct entry from the CSF.  
A plausible way of drug distribution into the brain would be via the transependymal flow 
close to the injection site. The transependymal flow can be defined as the motion of fluids 
or molecules across the ependymal layer of cells that surround the ventricles (João 
Casaca-Carreira et al., 2017). The CSF-brain barrier is a relatively easy way for molecules 
to penetrate the brain, as ependymal cells are not joined by tight junctions (Jiménez et 
al., 2014). Therefore, diffusion or bulk flow, which are the two suggested flow 
mechanisms, between CSF and brain parenchyma, is not tightly regulated. The 
transependymal flow, as i.c.v. drug delivery route into brain tissue, was suggested by 
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several previous studies (João Casaca-Carreira et al., 2017; Proescholdt et al., 1999; 
Westerhout et al., 2012).  
 
Indeed, the quantification of the ETX concentration in the brain tissue, revealed similar 
drug levels after i.c.v. and i.v. application of the same doses in both hemispheres  
(fig. 3.10). These results would contradict the assumption of direct brain tissue 
penetration by i.c.v. applied substances close to the injection site. However, we suspect 
methodological errors during the brain sample preparation for HPLC analysis. The 
control samples, collected after vehicle injections, showed contaminations of ETX, which 
could not be retraced (cf. supplementary data; tab. S.2). Therefore, we evaluated the 
results of the measured ETX concentrations in the brain as inconclusive and further 
measurements utilizing an improved method would be necessary. Particularly the 
sample collection and preparation must be improved as these steps create the highest 
risk of unwanted contaminations. 
 
To visually retrace substance distribution, throughout the CNS, we injected the dye Fast 
Green (FG) into the right LV of three GAERS rats and collected the brains at different time 
points (5min, 1h and 4h after FG administration). Although the physicochemical 
properties of a substance are decisive for distribution characteristics, and FG 
distribution dynamics can thus not be directly transferred to ETX, we believe our i.c.v. 
dye injections support the idea of the direct distribution of ETX in relevant brain 
structures. The rat brains were snap-frozen immediately after dissection. Therefore, the 
CSF was kept in the intracranial cavities and remained visible. The evaluation of the 
brain samples directly after FG injection indicates a fast distribution of FG throughout 
the CSF, as intensively stained CSF can be observed in all visible ventricles, i.e. in the right 
and left LV and the third ventricle (fig. 3.12A). The visual inspection of FG distribution 
across the brain supports the assumption of transependymal substance distribution. We 
found that FG penetration into the brain parenchyma originates at the right LV and the 
third ventricle. However, at the left LV, i.e. contralateral to the injection site, hardly any 
FG staining could be observed. FG penetration originating from the subarachnoid space 
(SAS) was also not obvious.  
The CSF exits the LVs by bulk flow directly into the third ventricle, from where it 
circulates into the fourth ventricles, and finally moves via the cisterns surrounding the 
cerebellum into the cranial and spinal SAS (cf. fig. 1.3). However, only minimal CSF is 
exchanged between the two LVs via reflux mechanisms (Pardridge, 2020). Therefore, we 
suggest an uneven distribution of FG in the ventricular system, because the molecules 
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move with the CSF circulation. This is in line with the observation that FG staining of 
brain parenchyma was largely restricted to the side of injection. Unilateral substance 
distribution after i.c.v. application has already been described in other studies (Shokry 
et al., 2016; Yan et al., 1994). This unilateral distribution of ETX may explain the sub-
total seizure suppression after i.c.v. application that we have observed. It is thus 
tempting to speculate, that bilateral i.c.v. administration of AEDs at low doses may 
achieve even more rigorous seizure suppression. 
We found that the distance of penetration into brain tissue from the walls of the 
ventricular system at the ipsilateral site increased with time (fig. 3.12A, B, and C). 
Excitingly, the distribution dynamics of FG match nicely with the previously described 
time course of seizure suppression by i.c.v. applied AEDs. Whereas no prominent 
staining was detected in VB, NRT, or deep layers of somatosensory cortex immediately 
after dye injection, staining was prominent already after one hour in deep layers of the 
cortex and widespread in all structures including thalamic areas after 4 hours. 
 
The analysis of substance distribution in the brain after i.c.v. application supported our 
hypothesis that substances can directly penetrate into the brain parenchyma following 
IT administration. However, at the same time, this route of drug distribution seems 
restricted to brain areas in the vicinity of the ventricular system, which narrows the CNS 
disorders that can be targeted by i.c.v. drug application. The distribution speed of 
molecules in the tortuous extracellular space probably affects the antiepileptic action of 
therapeutic agents (e.g. timing effects and target areas), which must be carefully 
considered when choosing this application route. Nevertheless, the ETX concentration 
in plasma and CSF after systemic administration of 100 mg/kg was more than 15 times 
higher than after 2 mg/animal i.c.v. treatment (fig. 3.11). Still, up to 68% seizure 
reduction can be achieved by low dose i.c.v. drug injection. Potentially bilateral drug 
injection could even enhance the anti-absence efficacy of IT applied ETX. Hence, our 
results clearly show that the administration of substances directly into the cerebrospinal 
fluid could be a potential alternative for systemic therapy within selected diseases of the 
CNS. 
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Figure 4.1: Cartoon illustrating the flow of CSF through the ventricular 
system and its spatial relationship with structures relevant in absence 
epilepsy  
A) The brain areas relevant for the emergence and maintenance of SWDs are 
highlighted: NRT, nucleus reticularis thalami; VB, ventrobasal thalamus; S1 
Cortex, primary somatosensory cortex. The arrows indicate the direction of the 
slow CSF circulation. B) Magnification of boxed area in A, showing the three 
meninges (dura mater, arachnoid mater and pia mater) and the subarachnoid 
space. The arachnoid mater forms the major meningeal diffusion barrier 
between the epidural space and the CNS. 
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4.6 Seizure suppressing effects of i.c.v. applied neuropeptides.  
Neuropeptide Y 
Due to their neuromodulating properties several neuropeptides have been suggested as 
potent anticonvulsant substances (Clynen et al., 2014). 
The endogenous peptides show antiepileptic efficacy at extremely low doses, and they 
are additionally hardly affected by active elimination mechanisms in the CNS (Kovac and 
Walker, 2013). These properties could make neuropeptides ideal candidates for IT drug 
applications. One of the most studied neuropeptides in the context of epilepsy is 
Neuropeptide Y (NPY). NPY supposedly suppresses epileptic activity by decreasing the 
excitability in cortical networks. The neuromodulator can dampen excitatory activity in 
the brain by reducing glutamate release through the activation of presynaptic Y2 
receptors (El Bahh et al., 2005) or by increasing GABAergic neurotransmission, in 
cortical areas, where the Y1 receptor is highly expressed (Bacci et al., 2002). 
In 2005 the published data of Stroud et al. confirmed that i.c.v. applied NPY induces a 
significant anti-absence effect in GAERS. The study showed that the epileptic animals 
spend on average ~20% of the recorded time (90min) in seizures after vehicle injection. 
After i.c.v. application of NPY the rats spent only 5-10% of the recorded time in seizures, 
which would amount to reduction by about 50%. Moreover, the group achieved similar 
results by only injecting the Y2 receptor agonists into the LV (Morris et al., 2007).  
Our analysis revealed that after NPY treatment, GAERS spent equivalent time in seizures 
compared to the literature, though this was not different from the seizure activity after 
vehicle injection (fig. 3.15B; left panel). Therefore, our experiments could not confirm a 
seizure suppressing effect in GAERS by i.c.v. applied NPY. It is noteworthy that animals 
in different GAERS colonies show variations in the severity of epilepsy (Powell et al., 
2014). Moreover, the experimental design working with GAERS can have a decisive 
effect on epileptic activity. Not only show the animals circadian variability in SWDs 
occurrence (fig. 3.3) but also stress factors, such as noise, handling, or the placement in 
a new cage that has previously hosted female rats or mice affect epileptic behavior in 
GAERS (Vergnes et al., 1991). These aspects could partially explain the discrepancies of 
baseline seizure occurrence between the GAERS rats in our experiments compared to 
the GAERS of the introduced study of Stroud et al. (2005). 
 
Moreover, it has been shown that the antiepileptic action of NPY varies with brain 
regions: The application of NPY into the secondary somatosensory (S2) cortex 
significantly reduced seizure activity in GAERS. In contrast, the local injection of NPY into 
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the VB thalamus increased the number of SWDs (van Raay et al., 2012). Thus, how NPY 
distributes in the brain tissue after i.c.v. application can profoundly influence the anti-
absence effect. Our evaluation of i.c.v. applied FG shows that substances can penetrate 
into the S2 cortex, but also into the VB thalamus after IT treatment (fig. 3.12). Provided 
that these distribution dynamics can be translated to NPY, the contradicting mechanisms 
of action in these brain areas could occlude an anti-absence effect. Finally, we cannot 
definitely answer the question, why our results for i.c.v. applied NPY deviate from those 
of Stroud et al. (2005). 
Somatostatin  
The neuropeptide somatostatin (SST) has also been suggested to have antiepileptic 
properties (Clynen et al., 2014). The receptor SST2 most probably mediates the 
anticonvulsant actions of SST in rats by suppressing presynaptic glutamate release 
(Kozhemyakin et al., 2013). Somatostatin receptors show ubiquitous distribution 
throughout the brain, including the thalamus and cortex (Srikant and Patel, 1981); 
however, the antiepileptic actions of SST appear mainly in the hippocampus (Tallent and 
Qiu, 2008). Indeed, it has been demonstrated that the pharmacological modulation of 
hippocampal activity can also reduce the incidences of SWDs in WAG/Rij rats 
(Tolmacheva et al., 2012). Still, i.c.v. application of SST had no antiepileptic effects in 
GAERS (fig. 3.15; right panel). The IT application of SST may be a possible solution in 
other epilepsy types as our FG staining showed that i.c.v. applied substances can nicely 
distribute into the hippocampus (fig. 3.12). This assumption is line with the finding of 
Mazarati and Telegdy (1992), showing that the i.c.v. application of SST (1.8 nmol) 
decreases the severity of seizures in picrotoxin-kindled rats (a model for human 
temporal lobe epilepsy).  
In summary our results suggest that the neuropeptides SST and NPY are unsuitable for 
IT treatment in absence epilepsy. 
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4.7 The epidural cup as alternative IT application route 
The brain and the spinal cord are enclosed by three meninges: the dura mater, the 
arachnoid mater, and the pia mater. The thick dura mater forms the outermost barrier, 
whereas the pia mater directly contacts the surface of the brain. Together with the pia 
mater the arachnoid mater, which lies in the middle of the meninges, encloses the 
subarachnoid space (SAS), which contains CSF (fig. 4.1). We hypothesized that the 
highest drug concentration after IT application can be found in the vicinity of the 
injection site. Hence, drug application into the SAS might be a possibility to increase the 
penetration of therapeutics into cortical areas. This application route could be 
advantageous in absence epilepsy, as pharmacological studies showed that the injection 
of ETX into the S1 cortex of GAERS robustly suppresses SWDs (Manning et al., 2004). 
Given the relatively small size of the SAS in rats, the direct application of active agents 
into the CSF is challenging. An alternative application technique to distribute active 
agents into the SAS, respectively, into the cortex, is transmeningeal pharmacotherapy 
(Tanganelli et al., 1992). This approach holds the advantage that the application of 
solutes onto the dura mater is minimally invasive and easy to implement. However, the 
solute must diffuse through all meninges in order to reach the brain. While the pia and 
the dura mater mainly consist of collagen and elastin fibers the arachnoid mater is 
composed of overlapping cells with frequent tight junctions (Bernards and Hill, 1990; 
Nabeshima et al., 1975). Hence the arachnoid mater forms the major meningeal diffusion 
barrier between the epidural space and the CNS.  
 
We tested the transmeningeal application route by implanting an epidural cup onto the 
dura mater (cf. Chapter 2.2; fig 2.2) and filling it with an ethosuximide solution  
(1 mg/animal or 2 mg/animal). The monitoring of seizures in GAERS after drug 
application into the cup, however, did not show any antiepileptic effect.  
To reach the SAS, the ETX must cross the meninges by diffusion, in contrast, the 
distribution of i.c.v. applied substances into the brain parenchyma is probably facilitated 
by bulk flow of the CSF (João Casaca-Carreira et al., 2017). Based on Fick’s law, the 
diffusion rate depends on the concentration differences, the strength of the barrier, the 
travel distance of molecules, and molecule size and solubility. Thus, we suspect that in 
order to enhance the diffusion rate and to reach therapeutical drug doses in the cortex, 
either the ETX concentration in the epidural cup has to be increased or the dura mater 
and arachnoid mater must be removed before applying the drug. 
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Although an antiepileptic effect by applying ETX on the cortex could not be 
demonstrated yet, we believe that further investigation of this application route would 
be beneficial. Regarding intracranial drug-releasing implants, a subcortical location 
would be surgically more accessible, less restricted by size compared to the ventricular 
system, and drug refill would be feasible.    
4.8 Method to investigate drug releasing implants 
The results from the presented study indicate that acute i.c.v. treatment with low drug 
dose ETX is significantly more effective in seizure suppression than systemic treatment 
with the same dose and would thus allow reduction of systemic drug exposure. We 
believe that the benefits of i.c.v. treatment may be even clearer for continuous treatment. 
However the permanent implantation of a ventricular catheter in humans holds a high 
infection risk of the CNS as the brain barriers are permanently interrupted (Chamberlain 
et al., 1997; Mead et al., 2014). The most common i.c.v. device in clinical use is the 
Ommaya reservoir, which is mostly used for intracranial chemotherapy (Sheldon and 
Ommaya, 1963). To widen the therapeutic spectrum of intracranial delivery of 
therapeutics, alternative application strategies have been investigated and the 
implementation of advanced biocompatible materials for IT drug delivery may be a 
potential improved method (Fenton et al., 2018). The demands for drug releasing 
materials are high as they must be biocompatible and ideally show a steady release 
within the therapeutic window that does not change with time (i.e zero-order release). 
 
The methodology for i.c.v. implantation and seizure analysis in GAERS, that have been 
established during this study, can now be used to test drug releasing materials in vivo. 
Based on the dose-response of GAERS to i.c.v. applied ETX and VPA, the release kinetics 
of the implants could be directly adapted. However, it is essential to note that our 
knowledge concerning tissue distribution mechanisms is still limited, and a steady 
release could affect the therapeutic drug concentrations required.  
Additionally, adverse effects of local drug exposure and material implantation in the CSF 
can be continuously observed by video monitoring and the introduced behavioral 
experiments (cf. Chapter 2.7).  
However, we showed that under chloral hydrate anesthesia, the epileptic activity of 
GAERS was suppressed for approximately five hours. The implantation of a drug-
releasing material requires that the animals are under anesthesia. Hence, to investigate 
the complete time course of the pharmacological effect of a drug-releasing implant, it 
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would be necessary to find an alternative anesthetic or to implement a material with a 
drug release, which only starts after more than 5-6 hours. 
4.9 Conclusion  
In the present study, we have examined in-depth whether the intrathecal drug delivery 
could in principle be an option for the treatment of epileptic disorders. To this end, we 
have systematically investigated the therapeutic effects of i.c.v. and subcortically applied 
substances in a well-validated rat model of absence epilepsy.  
 
We found that i.c.v. administration of ETX and VPA, the classical drugs in absence 
epilepsy, caused robust and dose-dependent reduction of SWDs. However, ETX showed 
after systemic treatment and for IT application prolonged and more efficient seizure 
suppression in GAERS compared to VPA. Additionally, we could show that i.c.v. 
treatment with ETX is significantly more effective in seizure suppression than systemic 
treatment with the same dose. 
Moreover, the localized application of the AED resulted in dramatically reduced systemic 
drug exposure compared to standard ETX therapy. These findings strongly argue against 
the idea that i.c.v. application simply represents a slow intravenous infusion (Pardridge, 
2016) and instead suggests that AEDs can penetrate into relevant brain regions directly 
from the CSF. Indeed, the visual retracing of substance distribution throughout the CNS 
supported the view that i.c.v. applied drugs cross the ependymal layer surrounding the 
ventricles and distribute into brain tissue close to the injection site. To which extend this 
occurs through passive diffusion or convective transport will have to be investigated 
further. Though, this drug distribution route would narrow the spectrum of epileptic 
disorders and CNS diseases in general that can be targeted by i.c.v. drug application to 
those with target regions in the vicinity of the ventricular system. As our dye injections 
indicated that i.c.v. drug injections may only affect the ipsilateral hemisphere, we believe 
that the anticonvulsant effect of i.c.v. treatment with AEDs maybe enhanced with 
bilateral drug injections. Furthermore, the continuous localized treatment via advanced 
drug releasing materials or application systems, which permit regulated release and 
reservoir fill up with little risk of infection, could increase the therapeutic efficiency 
(Fenton et al., 2018). It is thus possible that i.c.v. drug application may become an 
alternative for systemic therapy in selected CNS disorders.  
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As our data suggests that IT therapy is feasible through direct transportation of 
substances from the CSF into the brain tissue, this application method could especially 
hold therapeutic potential for substances that cannot cross the BBB. Although, we could 
not confirm an anti-absence effect by the i.c.v. applied neuropeptides NPY and SST other 
substances should be tested in order to explore this possibility. 
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Table S.2: Reference samples for HPLC analysis –  ETX concentration (μg/g) of (μg/ml ) in collected samples after 
ICV, IP, or IV drug injection of ringer solution. 
 IP(Saline)  IV(Saline)  ICV(Saline) 
CSF (μg/ml)  0  0  0 
Plasma (μg/ml ) 0  0  0 
Cortex (+) (μg/g) 0  0  6.0 
Cortex (-) (μg/g) 0  0  10.0 
Thalamus (+) (μg/g) 0  0  12.7 
Thalamus (-) (μg/g) 0  0  3.7 
 
Figure S.1: HPLC calibration chromatogram, to detect ETX 
in brain samples after animals were treated with the AED. 
The concertation of 54,6 µg/ml ETX dissolved in water was 
injected into the apparatus (detection at 249 nm). A clear 
peak for ETX is visible after 6.1 minutes. 
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